HomeBiosimilar Antibodies

Biosimilar Antibodies

Catalog No. Product Name Information Isotype
A2005 Pembrolizumab (anti-PD-1) Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD. Human IgG4
A2004 Atezolizumab (anti-PD-L1) Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD. Human IgG1
A2000 Cetuximab (anti-EGFR) Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW：145.781 KD. Human IgG1
A2002 Nivolumab (anti-PD-1) Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD. Human IgG4
A2381 Serplulimab (Anti-PDCD1 / PD-1 / CD279) Serplulimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.5 kD. Human IgG4SP
A2006 Bevacizumab (anti-VEGF) Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD. Human IgG1
A2007 Trastuzumab (anti-HER2) Trastuzumab (anti-human HER2) is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD. Human IgG1
A2009 Rituximab (anti-CD20) Rituximab (anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD. Human IgG1
A2001 Ipilimumab (anti-CTLA-4) Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD. Human IgG1
A2015 Avelumab (anti-PD-L1) Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa. Human IgG1
A2012 Tocilizumab (anti-IL-6R) Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD. Human IgG1
A2013 Durvalumab (anti-PD-L1) Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa. Human IgG1
A2027 Daratumumab (anti-CD38) Daratumumab (anti-CD38) is a recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug which is indicated for the treatment of adult patients with multiple myeloma. MW =145.4 kDa. Human IgG1
A2010 Adalimumab (anti-TNF-alpha) Adalimumab (anti-TNF-alpha) is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha, MW: 144.19 KD. Human IgG1
A2008 Pertuzumab (anti-HER2) Pertuzumab (anti-HER2), a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD. Human IgG1
A2493 Anti-FLT3 / CD135 Anti-FLT3 / CD135 (IMC-EB10) is a fully human IgG1 monoclonal antibody, targeting the FLT3 tyrosine kinase receptor (CD135) with potential antineoplastic activity. It binds to FLT3 and blocks FLT3 ligand binding to FLT3 and subsequent FLT3 phosphorylation, which may result in the inhibition of FLT3-mediated signal transduction pathways. MW: 145.5 KD. Human IgG1
A2028 Tiragolumab (anti-TIGIT) Tiragolumab (anti-TIGIT) (RG6058, MTIG7192A) is a humanized IgG1/kappa monoclonal antibody that binds TIGIT to prevent its interaction with its ligand PVR (CD155). Human IgG1, κ
A2024 Ustekinumab (anti-IL-12/IL-23) Ustekinumab (CNTO 1275) is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody used to treat psoriasis. MW=145.6 kDa. Human IgG1
A2003 Ramucirumab (anti-VEGFR2) Ramucirumab is a monoclonal antibody of the IgG1 class that binds to VEGF-R2 and prevents its activation. The IC50 value for blocking KDR binding to VEGF is 0.8 nM for ramucirumab, MW: 143.6 KD. human IgG1
A2019 Infliximab (anti-TNF-alpha) Infliximab (anti-TNF-alpha) is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble and transmembrane forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. MW=144.2 kDa. Chimeric IgG1
A2016 Camrelizumab (anti-PD-1) Camrelizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD. Human IgG4
A2036 Magrolimab (anti-CD47)

Magrolimab (anti-CD47) (5F9, GS-4721,Hu5F9 G4,ONO 7913) is a first-in-class macrophage immune checkpoint inhibitor that mainly binds to N-terminal pyroglutamate of CD47.

 Human IgG4
A2029 Relatlimab (anti-LAG-3) Relatlimab (BMS-986016, RELA) is a human LAG-3 specific monoclonal antibody that binds to LAG-3 on T cells, restoring effector function of exhausted T cells. Human IgG4, κ
A2025 Secukinumab (anti-IL-17A) Secukinumab (anti-IL-17A) (AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa. Human IgG1
A2018 Panitumumab (anti-EGFR) Panitumumab (anti-EGFR, ABX-EGF) is a recombinant, fully human IgG2 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR). Human IgG2
A2037 Sabatolimab (anti-TIM-3)

Sabatolimab (anti-TIM-3) (MBG453, NVP-MBG453) is a high-affinity, humanized IgG4 antibody targeting TIM-3 on the surface of T-cells.

 Human IgG4, κ
A2031 Sacituzumab (anti-Trop-2) Sacituzumab (anti-Trop-2) is a fully humanized IgG1 kappa monoclonal antibody that binds Trop-2. Human IgG1
A2506 Patritumab (Anti-ERBB3 / HER3) Patritumab (Anti-ERBB3 / HER3) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab shows a synergy with Cetuximab, potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. MW: 145.5 KD. Human IgG1
A2033 Vibostolimab (anti-TIGIT) Vibostolimab (anti-TIGIT, MK-7684) is a humanized monoclonal antibody that binds to the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), blocking the interaction between TIGIT and its ligands, CD112 and CD155, thereby activating T lymphocytes which help to destroy tumor cells. Human IgG1, κ
A2011 Sarilumab (anti-IL-6Rα) Sarilumab (anti-IL-6Rα) is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD. Human IgG1
A2035 Sintilimab (anti-PD-1) Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Human IgG4, κ
A2020 Denosumab (anti-RANK ligand) Denosumab (anti-RANK ligand) (AMG-162) is a fully human monoclonal antibody that selectively inhibits primate RANKL. Denosumab inhibits the ability of human RANKL (143–317) to stimulate the formation of osteoclasts derived from murine RAW 264.7 cells with an IC50 value of 1.64 nM. human IgG1
A2023 Obinutuzumab (anti-CD20) Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin. MW : 146.1 kD. Human IgG1 isotype control
A2021 Tremelimumab (anti-CTLA-4) Tremelimumab (Ticilimumab, CP-675,206) is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes. Human IgG2
A2017 Spartalizumab (anti-PD-1) Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD. Human IgG4
A2038 Dupilumab (anti-IL-4Rα) Dupilumab (anti-IL-4Rα) is a fully human anti–interleukin-4 receptor α monoclonal antibody that inhibits both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling through blockade of the shared IL-4α subunit. Human IgG4, κ
A2022 Cemiplimab (anti-PD-1) Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response. Human IgG4
A2362 Anti-SCFR / c-Kit / CD117 Anti-SCFR / c-Kit / CD117 is a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) with potential antineoplastic activity. MW : 150 kD. Human IgG1
A2030 Siltuximab (anti-IL-6) Siltuximab (anti-IL-6) (CNTO 328) is a human-mouse chimeric monoclonal antibody that binds human interleukin-6 (IL-6). Human IgG1, κ
A2043 Evolocumab (anti-PCSK9) Evolocumab (anti-PCSK9) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases. Human IgG2
A2039 Isatuximab (anti-CD38)

Isatuximab (anti-CD38) (SAR650984, hu38SB19) is an IgG1-derived monoclonal antibody that binds to a specific extracellular epitope of CD38 receptor with a kd of 0.12 nM.

 Human IgG1, κ
A2042 Pamrevlumab (anti-CTGF) Pamrevlumab, a recombinant human antibody that binds to connective tissue growth factor (CTGF) has emerged as a potential therapy for idiopathic pulmonary fibrosis (IPF). Human IgG1, κ
A2032 Brodalumab (anti-IL17RA) Brodalumab (anti-IL17RA) (KHK4827, AMG 827) is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R). Human IgG2
A2524 Anti-CXCL8 / IL-8 Anti-CXCL8 / IL-8 (ABX-IL8) is a antibody targeting CXCL8. MW: 145.5 KD. Human IgG2SA
A2041 Emapalumab (anti-IFNγ) Emapalumab (anti-IFNγ), a monoclonal antibody directed against IFNγ, is the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory. Human IgG1
A2034 Elotuzumab (anti-SLAMF7) Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity. Human IgG1, κ
A2045 Vedolizumab (anti-α4β7-integrin) Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease. Human IgG1
A2586 Enapotamab (Anti-AXL / UFO) Enapotamab(Anti-AXL / UFO) is a highly specific rabbit polyclonal antibody that targets receptor tyrosine kinase AXL (UFO). It demonstrates potent activity in immunotherapeutic strategy for the treatment of sarcomas. MW :145.42 KD. Human IgG1
A2497 Bemarituzumab (Anti-FGFR2 / CD332) Bemarituzumab (Anti-FGFR2 / CD332) is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. MW: 145.24 KD. Human IgG1
A2498 Aprutumab (Anti-FGFR2 / CD332) Aprutumab (Anti-FGFR2 / CD332) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research. MW: 78.2 KD. Human IgG1
A2695 Anti-TGFb1 (M7824) Anti-TGFb1 (M7824) is a bifunctional monoclonal antibody targeting programmed death ligand 1 (PD-L1) and transforming growth factor beta 1 (TGFb1). It exhibits anti-tumor efficacy against breast and colon carcinomas. Human IgG1
A2513 Anti-ENTPD1 / CD39 Anti-ENTPD1 / CD39 (TTX-030) is a fully human monoclonal antibody directed targeting the cell surface receptor CD39. It specifically binds to the CD39 antigen and inhibits both the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP) and the subsequent generation of immunosuppressive extracellular adenosine in the tumor microenvironment (TME). MW: 145.5 KD. Human IgG4SP
A2451 Ordesekimab (Anti-IL-15) Ordesekimab (Anti-IL-15) is a fully human monoclonal antibody targeting IL-15 and inhibiting the interaction of IL-15 with the IL-2Rβ. It has the potential for treatment of nonresponsive celiac disease (NRCD). MW :143.82 KD. Human IgG1
A2467 Telisotuzumab (Anti-HGFR / c-Met) Telisotuzumab (Anti-HGFR / c-Met) is a monoclonal antibody that targets c-Met. MW: 145.64 KD. Human IgG1
A2468 Onartuzumab (Anti-HGFR / c-Met) Onartuzumab (Anti-HGFR / c-Met) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity. MW: 144.64 KD. Human IgG1
A2469 Rilotumumab (Anti-HGF / SF) Rilotumumab (Anti-HGF / SF) is a monoclonal antibody that inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research. MW: 145.5 KD. Human IgG2SA
A2569 Plozalizumab (Anti-CCR2 / CD192) Plozalizumab (Anti-CCR2 / CD192) is a specific humanized monoclonal antibody targeting CCR2. Plozalizumab can be used for malignant melanoma research. MW:145.5 KD. Human IgG1
A2366 Zilovertamab (Anti-ROR1) Zilovertamab (Anti-ROR1) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling with potential antineoplastic activity. MW: 145.5 kD. Human IgG1
A2372 Apamistamab (Anti-PTPRC / CD45) Apamistamab (Anti-PTPRC / CD45) is an IgG1 anti-CD45 monoclonal antibody (MoAb). Note: This antibody is not labeled with the radioisotope iodine (-131). MW: 145.5 kD. Human IgG1
A2534 Lacnotuzumab (Anti-CSF1 / M-CSF) Lacnotuzumab (Anti-CSF1 / M-CSF) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1, that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis. MW: 150 KD. Human IgG1
A2573 Carlumab (Anti-CCL2 / MCP1) Carlumab (Anti-CCL2 / MCP1) is a humanised monoclonal antibody targeting CCL2 with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer. MW:145.5 KD. Human IgG1
A2316 Belimumab (Anti-TNFSF13B / BAFF / CD257) Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa. Human IgG1
A2328 Belantamab (Anti-TNFRSF17 / BCMA / CD269) Belantamab (Anti-TNFRSF17 / BCMA / CD269) is a humanized monoclonal antibody directed against the B-cell maturation antigen (BCMA) that can be used in the synthesis of an antibody-drug conjugate (ADC), Belantamab mafodotin. MW : 145.5 KD. Human IgG1
A2378 Rinucumab (Anti-PDGFRB / CD140b) Rinucumab (Anti-PDGFRB / CD140b) is an anti-platelet-derived growth factor receptor beta (anti-PDGFR-beta) monoclonal antibody and has a potential to study neovascular age-related macular degeneration. MW: 145.5 kD. Human IgG4SP
A2397 Clivatuzumab (Anti-MUC1) Clivatuzumab (Anti-MUC1) is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers. MW: 145.5 kD. Human IgG1
A2430 Pascolizumab (Anti-IL-4) Pascolizumab (Anti-IL-4) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for asthma research. MW: 145.5 kD. Human IgG1
A2517 Begelomab (Anti-DPP4 / CD26) Begelomab (Anti-DPP4 / CD26) is a monoclonal antibody targeting DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy. MW: 145.5 KD. Human IgG2SA
A2813 Anti-Amyloid Beta (CSIRO anti-amyloid Beta scFv) Anti-Amyloid Beta (CSIRO anti-amyloid Beta scFv) is a recombinant monoclonal antibody in a single chain fragment variable (scFv) against amyloid beta, has the potential to be used in Alzheimer's disease (AD) research. MW : 145.14 KD. Human IgG1
A3069 Tenatumomab (Anti-Tenascin C) Tenatumomab (Anti-Tenascin C) is a murine monoclonal antibody targeting tenascin-C. It has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach. MW :146.48 KD. Human IgG1
A2814 Cudarolimab (Anti-TNFRSF4 / OX40 / CD134) Cudarolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic fully human anti-OX40 (tumor necrosis factor receptor superfamily member 4, TNFRSF4, CD134, OX40L receptor) with potential immune checkpoint inhibitory and antineoplastic activities. MW : 145.94 KD. Human IgG1
A3070 Marstacimab (Anti-TFPI) Marstacimab (Anti-TFPI) is a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI). It can be used for the research of hemophilia. MW :142.94 KD. Human IgG1
A2815 Dalotuzumab (Anti-IGF1R / CD221) Dalotuzumab (Anti-IGF1R / CD221) is a recombinant humanized monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. MW : 146.78 KD. Human IgG1
A3071 Anti-TGFb1 (NIS793) Anti-TGFb1 (NIS793) is a monoclonal antibody targeting TGF-β. It can be used in metastatic melanoma and non-small cell-lung cancer. MW :143.78 KD Human IgG1
A2816 Visilizumab (Anti-CD3) Visilizumab (Anti-CD3) is a humanized, non-Fc receptor (FcR)-binding IgG2 monoclonal antibody (MoAb) directed against CD3 with potential immunosuppressive activity. Visilizumab has the potential to be used for ulcerative colitis and Crohn's disease research. MW : 144.62 KD. Human IgG2SA
A3072 Zampilimab (Anti-TGM2 / Transglutaminase 2) Zampilimab (Anti-TGM2 / Transglutaminase 2) is a monoclonal antibody targeting transglutaminase 2 (TG2). It has potential application in renal transplant. MW :143.48 KD. Human IgG4SP
A2817 Anti-CD34 Anti-CD34 is a humanized monoclonal antibody against CD34 surface antigen on human stem cells. MW: 145.9 KD. Human IgG1
A3073 Etigilimab (Anti-TIGIT) Etigilimab (Anti-TIGIT) is an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). It can be used in treatment of advanced or metastatic solid tumors. MW :144.84 KD. Human IgG1
A2818 Felzartamab (Anti-CD38) Felzartamab (Anti-CD38) is a fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. MW : 143.66 KD. Human IgG1
A2819 Mezagitamab (Anti-CD38) Mezagitamab (Anti-CD38) is a human, non-agonistic immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) with potential immunomodulating and antineoplastic activities. MW : 144.44 KD. Human IgG1
A3075 Tilavonemab (Anti-Tau) Tilavonemab (Anti-Tau) is a humanised antibody that targets tau. It can be used in the study of Alzheimer's disease. MW :146.06 KD. Human IgG1
A2820 Tregalizumab (Anti-CD4) Tregalizumab (Anti-CD4) is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs). Tregalizumab can be used in the research of autoimmune diseases. MW : 147.42 KD. Human IgG1
A2821 Anti-CD4 (TRX1) Anti-CD4 (TRX1) is a non-depleting monoclonal IgG1 antibody against CD4. MW : 145.98 KD. Human IgG1
A3077 Tilogotamab (Anti-TNFRSF10B / TRAILR2 / CD262) Tilogotamab (Anti-TNFRSF10B / TRAILR2 / CD262) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). It can be used for the research of multiple myeloma (MM). MW :144.88 KD. Human IgG1
A2822 Depemokimab (Anti-IL-5) Depemokimab (Anti-IL-5) is a humanized monoclonal antibody (IgG1, kappa) directed against IL-5. Depemokimab can be used for research of asthma. MW : 145.8 KD. Human IgG1
A3078 Anti-F3 / Factor III / Tissue Factor / CD142 (TNX-832) Anti-F3 / Factor III / Tissue Factor / CD142 (TNX-832) is humanized form of an antibody capable of targeting tissue factor (coagulation factor F3). It is useful in treating conditions, such as tumor progression.MW :144.34 KD. Human IgG4SP
A2823 Divozilimab (Anti-CD20) Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20) with the potential to be used in multiple sclerosis research. MW : 145.26 KD. Human IgG1
A3079 Benufutamab (Anti-TNFRSF10B / TRAILR2 / CD262) Benufutamab (Anti-TNFRSF10B / TRAILR2 / CD262) is an agonistic antibody specificly targeting death receptor 5 (DR5).It has antitumor effects and can be used for the research of multiple myeloma (MM). MW :1145.12 KD. Human IgG1
A2824 Letaplimab (Anti-CD47) Letaplimab (Anti-CD47) is a human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. MW : 142.88 KD. Human IgG4SP
A2825 Ligufalimab (Anti-CD47) Ligufalimab (Anti-CD47) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.58 KD. Human IgG4SP
A3081New Anti-CAPRIN1 Anti-CAPRIN1 is a humanized antibody targeting CAPRIN-1. It is used as a novel and universal target for cancer therapies. MW :141.44 KD. Human IgG1
A2826 Domagrozumab (Anti-GDF8 / Myostatin) Domagrozumab (Anti-GDF8 / Myostatin) is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab has the potential to be used in research of duchenne muscular dystrophy (DMD). MW : 143.96 KD. Human IgG1
A3082 Toripalimab (Anti-PDCD1 / PD-1 / CD279) Toripalimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody targeting PD-1. It has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma. 147.3 KD. Human IgG4SP
A2827 Urabrelimab (Anti-CD47) Urabrelimab (Anti-CD47) is a human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. MW : 145.46 KD. Human IgG4SP
A3083 Anti-TNFRSF4 / OX40 / CD134 (BMS-986178) Anti-TNFRSF4 / OX40 / CD134 (BMS-986178) is a fully human immunoglobulin monoclonal antibody targeting OX40. It is used in treatment of in patients with advanced solid tumors. MW :150 KD. Human IgG1
A3084 Torudokimab (Anti-IL-33) Torudokimab (Anti-IL-33) is a fully human monoclonal antibody targeting human IL-33. It can be used in research of atopic dermatitis. MW :145.22 KD. Human IgG4SP
A3085 Tozorakimab (Anti-IL-33) Tozorakimab (Anti-IL-33) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. It can be used to research chronic obstructive pulmonary disease. MW :144.54 KD. Human IgG1
A2830 Gatralimab (Anti-CD52) Gatralimab (Anti-CD52) is an IgG1 anti-CD52 monoclonal antibody with the potential to treat Symptomatic Osteoarthritis. MW : 145.0 KD. Human IgG1
A3086 Anti-Amyloid Beta (U.Illinois scFv59) Anti-Amyloid Beta (U.Illinois scFv59) is a single-chain antibody targeting amyloid-β (Aβ) protein. It can be used in Alzheimer's disease (AD) research. MW :142.56 KD Human IgG1
A2831 Anti-CD59 Anti-CD59 is a humanized monoclonal antibody against CD59 with the potential to treat anti-tumour activity. MW: 145.08 KD. Human IgG1
A3087 Lucatumumab (Anti-TNFRSF5 / CD40) Lucatumumab (Anti-TNFRSF5 / CD40) is a fully human antagonist monoclonal antibody, targeting CD40. It exhibits clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research. MW :150 KD. Human IgG1
A2832 Domvanalimab (Anti-TIGIT) Domvanalimab (Anti-TIGIT) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) with potential immune checkpoint inhibitory activity. MW : 145.12 KD. Human IgG1
A3088 Mitazalimab (Anti-TNFRSF5 / CD40) Mitazalimab (Anti-TNFRSF5 / CD40) a human agonist IgG1 antibody targeting CD40. It enhances the anti-tumor efficacy of a model cancer vaccine. MW :143.44 KD. Human IgG1
A2833 Donanemab (Anti-Amyloid Beta) Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research. MW : 145.36 KD. Human IgG1
A3089 Ravagalimab (Anti-TNFRSF5 / CD40) Ravagalimab (Anti-TNFRSF5 / CD40) is a monoclonal antibody targeting CD40. It can be used for research of Crohn's disease. MW :146.04 KD. Human IgG1
A2834 Grisnilimab (Anti-CD7) Grisnilimab (Anti-CD7) is an IgG2a monoclonal antibody against CD7. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA. MW : 144.72 KD. Human IgG2SA
A3090 Anti-DCSTAMP Anti-DCSTAMP is an antibody targeting Dendritic cell-specific transmembrane protein, DC-STAMP. It is essential for cell-to-cell fusion to form multinucleated osteoclasts (OCs) during osteoclastogenesis. MW :146.2 KD. Human IgG1
A2835 Dostarlimab (Anti-PDCD1 / PD-1 / CD279) Dostarlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 ((PD-1  programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.18 KD. Human IgG4SP
A3091 Anti-GAD65 Anti-GAD65 is an autoantibody targeting glutamic acid decarboxylase (GAD65). It is used in treatment of Stiff person syndrome (SPS). MW :146.38 KD. Human IgG1
A2836 Iladatuzumab (Anti-CD79b) Iladatuzumab (Anti-CD79b) is a humanized IgG1 monoclonal antibody against CD79 B, a cell-surface antigen expressed on mature B cells. MW : 145.18 KD. Human IgG1
A3092 Anti-MICB Anti-MICB is an antibody that specifically target human major histocompatibility complex class I chain-related A and B (MICA/B). It can be used in treating a cancer. MW :143.66 KD. Human IgG2SA
A2837 Anti-CD83 Anti-CD83 is a humanized monoclonal antibody against CD83 with the potential to treat auto-immune diseases. MW: 144.8 KD. Human IgG2SA
A3093 Tabalumab (Anti-TNFSF13B / BAFF / CD257) Tabalumab (Anti-TNFSF13B / BAFF / CD257) is a humanised monoclonal antibody BAFF (B-cell activating factor). It can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus. MW :146.2 KD. Human IgG4SP
A2838 Anti-CD9 Anti-CD9 is a humanized monoclonal antibody against CD9 with potential anti-tumor activity. MW: 145.98 KD. Human IgG1
A3094 Anti-TNFSF14 / LIGHT / CD258 (SAR252067) Anti-TNFSF14 / LIGHT / CD258 (SAR252067) is a fully human monoclonal antibody targeting LIGHT. It can be used in treatment of treatment of ulcerative colitis and crohn's disease. MW :141.8 KD. Human IgG1
A2839 Anti-CDH1 / E-cadherin / CD324 Anti-CDH1 / E-cadherin / CD324 is an IgG1 monoclonal antibody against E-cadherin, an epithelial adhesion molecule. MW: 146.6 KD. Human IgG1
A3095 Anti-TNFSF2 / TNFa (CDP571) Anti-TNFSF2 / TNFa (CDP571) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA). MW :146.9 KD. Human IgG4SP
A2841 Cergutuzumab (Anti-CEACAM5 / CEA / CD66e) Cergutuzumab (Anti-CEACAM5 / CEA / CD66e) is a humanized monoclonal antibody which targets Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) with immunostimulating and antineoplastic activities. MW : 146.48 KD. Human IgG1
A3097 Anti-TNFSF2 / TNFa (CMAB008) Anti-TNFSF2 / TNFa (CMAB008) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA). MW :147.16 KD. Human IgG1
A2842 Ebdarokimab (Anti-IL-12b) Ebdarokimab (Anti-IL-12b) is a fully human monoclonal antibody (mAb) targeting Interleukin-12/Interleukin-23 (IL-12/IL-23) pathway. Ebdarokimab has the potential to treat moderate to severe plaque psoriasis. MW : 145.6 KD. Human IgG1
A3098 Anti-TNFSF2 / TNFa (ESBA 105) Anti-TNFSF2 / TNFa (ESBA 105) is an antibody targeting tumor necrosis factor (TNF).It has an efficient intraocular penetration to anterior and posterior region of eye. MW :145.14 KD. Human IgG1
A2843 Ebronucimab (Anti-PCSK9) Ebronucimab (Anti-PCSK9) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) used to treat hyperlipidemia. MW : 144.76 KD. Human IgG1
A3099 Anti-TNFSF2 / TNFa (hMAK195) Anti-TNFSF2 / TNFa (hMAK195) is an antibody targeting tumor necrosis factor (TNF).It can be used in the treatment of rheumatoid arthritis (RA). MW :145.06 KD. Human IgG1
A2844 Anti-Clathrin Heavy Chain / CHC Anti-Clathrin Heavy Chain / CHC is a human monoclonal antibody against clathrin heavy chain (CHC) with potential anti-angiogenesis and anti-tumor activity. MW: 145.62 KD. Human IgG1
A3100 Ruplizumab (Anti-TNFSF5 / CD40L / CD154) Ruplizumab (Anti-TNFSF5 / CD40L / CD154) is a humanized monoclonal antibody targeting CD40L(TNF Receptor). It has the potential for systemic lupus erythematosus disease research. MW :145.68 KD. Human IgG1
A2845 Elsilimomab (Anti-IL-6 / IFNb2) Elsilimomab (Anti-IL-6 / IFNb2) is an IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab has the potential to be used in research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA). MW : 145.96 KD. Human IgG1
A3101 Vilobelimab (Anti-Complement C5) Vilobelimab (Anti-Complement C5) is a monoclonal antibody targeting C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. It may be used in studies related to sepsis, COVID-19, etc. MW :145.9 KD. Human IgG4SP
A2846 Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) is a monoclonal antibody against CD40 (also called TNFRSF5) with potential antitumor activity. MW: 143.74 KD. Human IgG1
A2847 Lendalizumab (Anti-Complement C5) Lendalizumab (Anti-Complement C5) is a proprietary antibody that targets the complement protein C5a with potential immunomodulating and anti-inflammatory activities. MW : 146.02 KD. Human IgG2SA
A3103 Anti-TrkB / NTRK2 Anti-TrkB / NTRK2 is an antibody targeting TrkB. It is used to improve nerve function, including treatment of peripheral neuropathies. MW :146.68 KD. Human IgG2SA
A2848 Enoticumab (Anti-DLL4) Enoticumab (Anti-DLL4) is a human monoclonal antibody directed against Delta-like ligand-4 (DLL4) with potential antineoplastic activity.It has been used to treat  advanced solid tumors MW : 146.48 KD. Human IgG1
A3105 Anti-TSPAN26 / CD37 (AGS67E) Anti-TSPAN26 / CD37 (AGS67E) is a fully human monoclonal antibody that targets CD37. It is used for the potential treatment of B/T-cell malignancies. MW :143.44 KD. Human IgG2SA
A3106 Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) is a monoclonal antibody targeting Integrin a5b1 (ITGA5 & ITGB1). It can be used in treatment of solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer. MW :145.52 KD. Human IgG4SP
A2851 Emactuzumab (Anti-CSF1R / M-CSFR / CD115) Emactuzumab (Anti-CSF1R / M-CSFR / CD115) is a humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R, CSF-1R, CD115), also known as macrophage colony-stimulating factor receptor (M-CSFR), with potential antineoplastic and immunomodulating activities MW : 146.94 KD. Human IgG1
A3107 Anti-VCAM1 / CD106 Anti-VCAM1 / CD106 is a conjugated liposome targeting vascular cell adhesion molecule (VCAM)-1. It serves as a drug delivery system with dual functions: targeted delivery and solubilizing capacity. MW :143.4 KD. Human IgG2SA
A2596 Tilvestamab (Anti-AXL / UFO) Tilvestamab (Anti-AXL / UFO) is a humanized antibody targeting AXL.Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas. MW :146.16 KD. Human IgG1
A2852 Anti-CSF1R / M-CSFR / CD115 (LY3022855) Anti-CSF1R / M-CSFR / CD115 (LY3022855) is a recombinant, immunoglobulin, human monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. MW : 179.2 KD. Human IgG1
A3108 Varisacumab (Anti-VEGFA) Varisacumab (Anti-VEGFA) is a human recombinant monoclonal antibody targeting VEGFA. It may be used in research of Microvascular complications of diabetes 1 (MVCD1). MW :145.62 KD. Human IgG1
A2597 Alsevalimab (Anti-B7-H4 / VTCN1) Alsevalimab (Anti-B7-H4 / VTCN1) is a human monoclonal antibody targeting B7-H4. It has potential antineoplastic and immune checkpoint inhibitory activities. MW :144.74 KD. Human IgG1
A2853 Gimsilumab (Anti-CSF2 / GM-CSF) Gimsilumab (Anti-CSF2 / GM-CSF) is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the myeloid cell growth factor and inflammatory mediator granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential immunomodulating activity. MW : 145.8 KD. Human IgG1
A3109 Alacizumab (Anti-VEGFR2 / KDR / CD309) Alacizumab (Anti-VEGFR2 / KDR / CD309) is a humanized monoclonal antibody targeting VEGFR2 / KDR / CD309 . It has anti-tumour effect in tumour growth. MW :144.08 KD. Human IgG1
A2598 Anti-CLEC4C (BIIB059) Anti-CLEC4C (BIIB059) is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). It can be used for cutaneous lupus erythematosus (CLE) study. MW :146.34 KD. Human IgG1
A2854 Lenzilumab (Anti-CSF2 / GM-CSF) Lenzilumab (Anti-CSF2 / GM-CSF) is a recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. MW: 145.72 KD. Human IgG1
A3110 Vulinacimab (Anti-VEGFR2 / KDR / CD309) Vulinacimab (Anti-VEGFR2 / KDR / CD309) is a monoclonal antibody targeting VEGFR-2. It has potential anti-angiogenesis and antineoplastic activities and can be used in the research of cancers. MW :145.38 KD. Human IgG1
A2599 Cixutumumab (Anti-IGF1R / CD221) Cixutumumab (Anti-IGF1R / CD221) is a humanized monoclonal antibody with high affinity that targets type-1-insulin-like growth factor receptor (IGF-1R).It shows broad-spectrum anti-tumour activity and can be used in studies of sarcomas, neuroblastoma, wilms tumor, lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer. MW :150 KD. Human IgG1
A2855 Namilumab (Anti-CSF2 / GM-CSF) Namilumab (Anti-CSF2 / GM-CSF) is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. MW: 145.78 KD. Human IgG1
A3111 Bapineuzumab (Anti-Amyloid Beta) Bapineuzumab (Anti-Amyloid Beta) is a monoclonal antibody targeting β-amyloid protein (APP). It can be used for the research of Alzheimer’s disease (AD). MW :140.16 KD. Human IgG1
A2600 Naratuximab (Anti-TSPAN26 / CD37) Naratuximab (Anti-TSPAN26 / CD37) is a humanized monoclonal antibody targeting CD37 (TSPAN26). It can be used to synthesize an ADC compound, naratuximab emtansine which is used in treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). MW : 150 KD. Human IgG1
A2856 Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7) Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7)  is a gut‐selective humanized monoclonal antibody targets β7 integrins with a potential to treat inflammatory bowel disease (IBD). MW: 144.3 KD. Human IgG1
A3112 Lecanemab (Anti-Amyloid Beta) Lecanemab (Anti-Amyloid Beta) is a humanized IgG1 monoclonal antibody targeting soluble aggregated amyloid beta (Aβ). It can be used for the research of Alzheimer's Disease. MW :147.06 KD. Human IgG1
A2601 Amivantamab (Anti-EGFR / c-Met) Amivantamab (Anti-EGFR / c-Met) is a human bispecific antibody targeting EGFR-MET.It has immune anticancer activity in non-small cell lung cancer (NSCLC). MW :146.1 KD. Human IgG1
A2857 Anti-Sphingosine-1-phosphate Anti-Sphingosine-1-phosphate is a human IgG1 monoclonal anti-Sphingosine-1-phosphate antibody that targets lysosphingolipids, thereby lowering the concentration of S1P in the extracellular fluid. MW: 145.74 KD. Human IgG1
A2602 Anti-LY75 / CD205 (CDX-1401) Anti-LY75 / CD205 (CDX-1401) human monoclonal antibodies targeting specific for CD205 (DEC-205). It is used to enhance anticancer immunity by exploiting the capacity of dendritic cells (DCs). MW :150 KD. Human IgG1
A2858 Finotonlimab (Anti-PDCD1 / PD-1 / CD279) Finotonlimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.38 KD. Human IgG4SP
A2859 Nurulimab (Anti-CTLA-4 / CD152) Nurulimab (Anti-CTLA-4 / CD152) is a monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4, CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.34 KD. Human IgG1
A2604 Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262) Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). It induces cell apoptosis of cancer cells and inhibits tumor growth and can be used for the research of cancer. MW :150 KD. Human IgG1
A2860 Zalifrelimab (Anti-CTLA-4 / CD152) Zalifrelimab (Anti-CTLA-4 / CD152) is a recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. MW: 144.48 KD. Human IgG1
A3116 Anti-GLP1R Anti-GLP1R is a humanized antibody targeting GLP-1 receptor (GLP-1R). It can be used in therapy for type 2 diabetes mellitus. MW : 144.5 KD. Human IgG1
A2861 Anti-CTLA-8 / IL-17a (CAT-2200) Anti-CTLA-8 / IL-17a (CAT-2200) is a human monoclonal antibody against IL-17A (interleukin-17A) that can potently neutralize the effects of recombinant and native human IL-17A. MW: 143.72. Human IgG1
A3117 Axatilimab (Anti-CSF1R / M-CSFR / CD115) Axatilimab (Anti-CSF1R / M-CSFR / CD115) is a humanized IgG4 antibody targeting CSF-1R. It can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases. MW :141.3 KD. Human IgG4SP
A2606 Disitamab (Anti-ERBB2 / HER2 / CD340) Disitamab (Anti-ERBB2 / HER2 / CD340) is a humanized monoclonal antibody targeting HER2. It can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin. It has antitumor and antineoplastic activities. MW :144.16 KD Human IgG1
A2862 Ixekizumab (Anti-CTLA-8 / IL-17a) Ixekizumab (Anti-CTLA-8 / IL-17a) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab has the potential to be used in research on plaque psoriasis. MW: 146.44 KD. Human IgG4SP
A2863 Netakimab (Anti-CTLA-8 / IL-17a) Netakimab (Anti-CTLA-8 / IL-17a) is a humanized monoclonal antibody against interleukin-17 (IL-17) with the potential to treat moderate to severe plaque psoriasis. MW: 145.74 KD. Human IgG1
A2864 Perakizumab (Anti-CTLA-8 / IL-17a) Perakizumab (Anti-CTLA-8 / IL-17a) is a humanized IgG1κ monoclonal antibody against interleukin-17A (IL-17A). MW: 145.8 KD. Human IgG1
A3120 Obexelimab (Anti-CD19) Obexelimab (Anti-CD19) is a humanized antibody targeting CD19. It can be used in research of autoimmune diseases and rheumatoid arthritis (RA). MW :147.24 KD. Human IgG1
A2609 Clazakizumab (Anti-IL-6 / IFNb2) Clazakizumab (Anti-IL-6 / IFNb2) is a monoclonal antibody targeting the IL-6 (interleukin-6). It inhibitsg the cytokine response to SARS-CoV-2 in COVID-19 and can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection. MW :145.24 KD. Human IgG1
A2610 Vobarilizumab (Anti-IL-6Ra / CD126) Vobarilizumab (Anti-IL-6Ra / CD126) is a monoclonal antibody targeting IL-6R. It can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. MW :78.2 KD. Human IgG1
A2866 Vunakizumab (Anti-CTLA-8 / IL-17a) Vunakizumab (Anti-CTLA-8 / IL-17a) is a recombinant human IgGκ monoclonal antibody that targets interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis. MW: 146.28. Human IgG1
A3122 Pritoxaximab (Anti-Shiga toxin (E.coli)) Pritoxaximab (Anti-Shiga toxin (E.coli)) is a human chimeric IgG1(kappa) antibody that target shiga toxin 1 and shiga toxin 2, produced by E. coli. It can be used in the treatment of hemolytic-uremic syndrome (HUS). MW :145.88 KD. Human IgG1
A2611 Oleclumab (Anti-NT5E / CD73) Oleclumab (Anti-NT5E / CD73) is a human IgG1λ monoclonal antibody targeting the CD73 function. It has an anti-tumor activity and can be used in treatment of advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), mutant non-small-cell lung cancer (NSCLC). MW :143.14 KD. Human IgG1
A2867 Fontolizumab (Anti-IFNg) Fontolizumab (anti-IFNg) is a humanized monoclonal antibody directed against interferon-gamma (IFN-g) with immunomodulatory activity. MW: 144.8. Human IgG1
A3123 Setoxaximab (Anti-Shiga toxin (E.coli)) Setoxaximab (Anti-Shiga toxin (E.coli)) is a mouse chimeric IgG1(kappa) antiboy that target shiga toxin 1 and shiga toxin 2, produced by E. coli. It can be used in the treatment of hemolytic-uremic syndrome (HUS). MW :147.08 KD. Human IgG1
A2612 Anti-PDGFB (MOR-8457) Anti-PDGFB (MOR-8457) is a monoclonal antibody targeting PDGF-BB. It can be used in research of liver fibrosis in mice. MW :143.56 KD. Human IgG1
A2868 Anti-CXCL10 / IP-10 (NI-0801) Anti-CXCL10 / IP-10 (NI-0801) is a fully human monoclonal antibody against chemokine (C-X-C motif) ligand 10 (CXCL10). It has the potential to treat primary biliary cholangitis. MW: 146.08. Human IgG1
A3124 Anti-HBsAg (OST 577) Anti-HBsAg (OST 577) is monoclonal antibody targeting HBV surface antigen (HBsAg). It has the potential for chronic hepatitis B research. MW :144.6 KD. Human IgG1
A2613 Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) is a fully humanized monoclonal antibody targeting B7-H1. It is used in research of advanced melanoma, non-small cell lung carcinoma, renal cell carcinoma, and ovarian cancer. MW :150 KD. Human IgG4SP
A3125 Foravirumab (Anti-Rabies virus GP) Foravirumab (Anti-Rabies virus GP) is a monoclonal antibody targeting rabies virus glycoprotein antigenic site III. It is suitable in treatment of rabies postexposure prophylaxis. MW :144.44 KD. Human IgG1
A2614 Anti-PMEL (Genentech anti-PMEL17) Anti-PMEL (Genentech anti-PMEL17) is a monoclonal antibody targeting human PMEL protein. It is used as a target for antibody drug conjugate (ADC) therapy in melanoma. MW :145.54 KD. Human IgG1
A3126 Rafivirumab (Anti-Rabies virus GP) Rafivirumab (Anti-Rabies virus GP) is a monoclonal antibody targeting rabies virus for the prophylaxis of rabies can be used for research of cocktails. MW :145.9 KD. Human IgG1
A2615 Anti-PMEL Anti-PMEL is a monoclonal antibody targeting human PMEL protein. It is used as a target for antibody drug conjugate (ADC) therapy in melanoma. MW :145.38 KD. Human IgG1
A2871 Foralumab (Anti-CD3e) Foralumab (Anti-CD3e) is a monoclonal antibody directed against cluster of differentiation 3 (CD3) epsilon with immunomodulatory activity. MW: 145.56 KD. Human IgG1
A3127 Motavizumab (Anti-RSV-F) Motavizumab (Anti-RSV-F) is a monoclonal antibody targeting human RSV (respiratory syncytial virus). It can be used in respiratory syncytial virus infection in high-risk infants research. MW :145.32 KD. Human IgG1
A2616 Inclacumab (Anti-P-Selectin / CD62p) Inclacumab (Anti-P-Selectin / CD62p) is a humanized monoclonal IgG4 antibody selectively targets P-selectin. It reduces cell adhesion showing potential for prevention of sickle cell disease (SCD). MW :150 KD. Human IgG4SP
A3128 Anti-Spike RBD Antibody (P16-A3) Anti-Spike RBD Antibody (P16-A3) is an antibody specifically targeting and binding to coronavirus S protein. It showed excellent and significantly better activity in coronaviruses diseases. MW :150 KD. Human IgG1
A2617 Rosopatamab (Anti-FOLH1 / PSMA) Rosopatamab (Anti-FOLH1 / PSMA) is a humanised monoclonal antibody targeting PSMA. It can be used in cancer research, particularly in prostate cancer. MW: 144.36. Human IgG1
A2873 Anti-ICAM3 / CD50 Anti-ICAM3 / CD50 is an IgG1 monoclonal antibody against intercellular adhesion molecules-3 (ICAM-3, also known as CD50)) with the potential to have anti-proliferative activities. MW: 145.22 KD. Human IgG1
A3129 Anti-Spike RBD Antibody (P20-B4) Anti-Spike RBD Antibody (P20-B4) is an antibody specifically targeting and binding to coronavirus S protein. It showed excellent and significantly better activity in coronaviruses diseases. MW :150 KD. Human IgG1
A2618 Anti-Siglec-15 / CD33L3 (NC318) Anti-Siglec-15 / CD33L3 (NC318) is a monoclonal antibody targeting Siglec-15. It can be used as a novel immune suppressor and a potential target for normalization cancer immunotherapy. MW :146.98 KD. Human IgG1
A2874 Anti-MUC17 Anti-MUC17 is an IgG1 monoclonal antibody against MUC17, a membrane-bound protein highly expressed on the surface of intestinal cells. MW: 146.66 KD. Human IgG1
A3130 Anti-Spike RBD Antibody (P17-A11) Anti-Spike RBD Antibody (P17-A11) is an antibody specifically targeting and binding to coronavirus S protein. It showed excellent and significantly better activity in coronaviruses diseases. MW :150 KD. Human IgG4SP
A2619 Lirentelimab (Anti-Siglec-8) Lirentelimab (Anti-Siglec-8) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). It can be used for the research of eosinophilic gastritis and duodenitis. MW :150 KD. Human IgG1
A3131 Anti-Nucleocapsid Antibody (N-9) Anti-Nucleocapsid Antibody (N-9) targets the nucleocapsid protein of coronavirus. It promotes IL-6 production in SARS-CoV-2-infected alveoli. It is used in acute respiratory distress syndrome MW :150 KD. Human IgG1
A2620 Utomilumab (Anti-TNFRSF9 / 4-1BB / CD137) Utomilumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human IgG2 monoclonal antibody targeting the T-cell costimulatory receptor 4-1BB/CD137. It can be used for the research of relapsed/refractory follicular lymphoma (FL), non-Hodgkin lymphomas (NHL). MW :142.78. Human IgG2SA
A2876 Frovocimab (Anti-PCSK9) Frovocimab (Anti-PCSK9) is a humanized IgG4 monoclonal antibody that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). MW: 146.88 KD. Human IgG4SP
A3132 Anti-Nucleocapsid Antibody (N-18) Anti-Nucleocapsid Antibody (N-18) is an antibody targeting the nucleocapsid protein of coronavirus. It is used in diagnosis with significantly associated with faster symptom resolution for COVID-19 patients. MW :150 KD. Human IgG1
A2621 Anti-ACVR1 / ALK-2 (DS-6016a) Anti-ACVR1 / ALK-2 (DS-6016a) monoclonal antibody targeting ALK-2. It can be used in the treatment of fibrodysplasia ossificans progressiva (FOP). MW :145.56. Human IgG1
A3133 Anti-Spike RBD Antibody (R14-F8) Anti-Spike RBD Antibody (R14-F8) is a monoclonal antibody that is specificly targeting for the spike receptor binding domain of SARS-CoV-2, recognizing both Wuhan-Hu-1 and the Indian (Delta) variant. MW :150 KD. Human IgG1
A2622 Anti-ACVR2A (Ab-14E1) Anti-ACVR2A (Ab-14E1) is rabbit polyclonal antibody targeting human ACVR2A. It can be used in research of human intestinal cancer and preeclampsia. MW :146.36 KD. Human IgG1
A2878 Gancotamab (Anti-ERBB2 / HER2 / CD340) Gancotamab (Anti-ERBB2 / HER2 / CD340) is a HER2-targeted PEGylated liposome that encapsulates doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells. MW: 143.6 KD. Human IgG1
A3134 Anti-Spike RBD Antibody (R16-F10) Anti-Spike RBD Antibody (R16-F10) is a monoclonal antibody that is specificly targeting for the spike receptor binding domain of SARS-CoV-2. It is useful tool to estimate the individual protection against severe acute respiratory syndrome voronavirus 2 (SARS-CoV-2) infection. MW :150 KD. Human IgG1
A2623 Prasinezumab (Anti-Alpha-synuclein) Prasinezumab (Anti-Alpha-synuclein) is a humanized IgG1 monoclonal antibody targeting aggregated α-synuclein.It has the potential for Parkinson's disease research. MW :150 KD. Human IgG1
A2879 Gatipotuzumab (Anti-MUC1) Gatipotuzumab (Anti-MUC1) is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1) with potential antineoplastic activity. MW: 146.58 KD. Human IgG1
A3135 Anti-Nucleocapsid Antibody (N-P10) Anti-Nucleocapsid Antibody (N-P10) is a monoclonal antibody targeting the SARS-CoV-2 nucleocapsid protein (NP).It has strong potential for use in the clinical detection of SARS-CoV-2 infection, whether the virus is wild-type or a variant of concern. MW :150 KD. Human IgG1
A2624 Nesvacumab (Anti-ANGPT2) Nesvacumab (Anti-ANGPT2) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically targets the Tie2 receptor ligand Angiopoietin-2 (Ang2). It has potential antitumor activity. MW :150 KD. Human IgG1
A3136 Anti-Nucleocapsid Antibody (N-P11) Anti-Nucleocapsid Antibody (N-P10) is a monoclonal antibody targeting the SARS-CoV-2 nucleocapsid protein (NP).It has strong potential for use in the clinical detection of SARS-CoV-2 infection, whether the virus is wild-type or a variant of concern. MW :150 KD. Human IgG1
A2625 Anti-TNFSF13 / APRIL / CD256 (BION-1301) Anti-TNFSF13 / APRIL / CD256 (BION-1301) is a humanized antibody targeting a proliferation Inducing Ligand (APRIL, TNFSF13). It can be used in the treatment of IgA nephropathy. MW :150 KD. Human IgG2SA
A3137 Anti-Spike RBD Antibody (R15-F7) Anti-Spike RBD Antibody (R15-F7) is a potent human antibody targeting the spike receptor binding domain of SARS-CoV-2 . It can be used in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MW :145.2 KD. Human IgG4SP
A2626 Enoblituzumab (Anti-B7-H3 / CD276) Enoblituzumab (Anti-B7-H3 / CD276) is a humanized IgG1κ monoclonal antibody targeting human B7-H3 protein. It can be used in the treatment of medullary thyroid cancer (MTC). MW :150 KD. Human IgG1
A2882 Geptanolimab (Anti-PDCD1 / PD-1 / CD279) Geptanolimab (Anti-PDCD1 / PD-1 / CD279) is an immunoglobulin G4 (IgG4) humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PD1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.4 KD. Human IgG4SP
A3138 Anti-Spike RBD Antibody (RP6-E3) Anti-Spike RBD Antibody (RP6-E3) is a monoclonal antibody that is specificly targeting for the spike receptor binding domain of SARS-CoV-2. It is useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. MW :80 KD. Human IgG1
A2627 Anti-Complement C5aR1 (G2_anti-C5aR) Anti-Complement C5aR1 (G2_anti-C5aR) is a rat monoclonal antibody that detects Complement 5a receptor (C5aR). It exhibit potent proinflammatory stimulus with immunomodulatory activities. MW :146.08 KD. Human IgG4SP
A2883 Gevokizumab (Anti-IL-1b) Gevokizumab (Anti-IL-1b) is an IgG2 humanized monoclonal antibody against the pro-inflammatory cytokine interleukin 1 beta (IL-1b) with anti-inflammatory activity. MW: 145.12 KD. Human IgG2SA
A3139 Anti-Spike RBD Antibody (RP6-E2) Anti-Spike RBD Antibody (RP6-E2) is a monoclonal antibody that is specificly targeting for the spike receptor binding domain of SARS-CoV-2. It is useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. MW :80 KD. Human IgG1
A2628 Anti-CDH6 / K-Cadherin (HKT288) Anti-CDH6 / K-Cadherin (HKT288) is a first-in-class antibody-drug conjugate (ADC) targeting CDH6. It has potential in advanced solid tumors research. MW :144.24 KD. Human IgG1
A2884 Giloralimab (Anti-TNFRSF5 / CD40) Giloralimab (Anti-TNFRSF5 / CD40) is an agonistic monoclonal antibody directed against the B-cell surface antigen CD40 with potential antineoplastic activity. MW: 145.26 KD. Human IgG1
A3140 Anti-Spike RBD Antibody (RP1-H5) Anti-Spike RBD Antibody (RP1-H5) is a monoclonal antibody that is specificly targeting for the spike receptor binding domain of SARS-CoV-2. It is useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. MW :80 KD. Human IgG1
A2629 Anti-CTSS / Cathepsin S (Fsn0503h) Anti-CTSS / Cathepsin S (Fsn0503h) is an antagonistic monoclonal antibody targeting cathepsin S. It has a potential to inhibit invasion of tumors, and targeting neovascularization in colorectal carcinoma. MW :144.28 KD. Human IgG1
A3141 Anti-Spike RBD Antibody (RP1-E4) Anti-Spike RBD Antibody (RP1-E4) is a monoclonal antibody that is specificly targeting for the spike receptor binding domain of SARS-CoV-2. It is useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. MW :80 KD. Human IgG1
A2630 Anti-CCR7 / CD197 (R707) Anti-CCR7 / CD197 (R707) is a fully human antibody targeting CCR7 signaling and function. It exhibits the potential to prevent acute graft-versus-host disease (aGVHD).MW :145.36 KD. Human IgG1
A2886 Demupitamab (Anti-ERBB1 / EGFR / HER1) Demupitamab (Anti-ERBB1 / EGFR / HER1) is a humanized monoclonal antibody (MoAb) against the human epidermal growth factor receptor (EGFR). MW: 144.8 KD. Human IgG1
A3142 Anti-Spike S1 Antibody (NCOV-S1P14-Fc) Anti-Spike S1 Antibody (NCOV-S1P14-Fc) is a mouse immunized antibody, targeting specific SARS-CoV-2 Spike protein RBD domain. It can be paired with other Anti-SARS-CoV-2 Spike S1 antibodies to detect SARS-CoV-2 Spike S1 protein. MW :80 KD. Human IgG1
A2631 Anti-IL-3Ra / CD123 (SNG-CD123A) Anti-IL-3Ra / CD123 (SNG-CD123A) is an antibody-drug conjugate targeting IL-3 alpha chain receptor (CD123). It is a potent antileukemic agent in treatment of acute myelogenous leukemia(AML). MW :146.14 KD. Human IgG1
A2887 Depatuxizumab (Anti-ERBB1 / EGFR / HER1) Depatuxizumab (anti-ERBB1/ EGFR / HER1) is a humanized monoclonal antibody (MoAb) against the human epidermal growth factor receptor (EGFR) with antineoplastic activity. MW: 144.54 KD. Human IgG1
A3143 Anti-MERS (2E6) Anti-MERS (2E6) is a human neutralizing antibody that targets competing for the binding of the virus Spike protein to the receptor (CD26). It is useful in inhibiting virus invasion into host cells. MW :150 KD. Human IgG1
A2632 Samalizumab (Anti-CD200) Samalizumab (Anti-CD200) is a humanized monoclonal antibody that specifically targets CD200. It can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research. MW :144.84 KD. Human IgG2SA
A3144 Anti-MERS (3A1) Anti-MERS (3A1) is a human monoclonal IgG1 antibody targeting the binding of MERS-CoV spike protein to DPP4 receptor. It is useful in inhibiting virus invasion into host cells. MW :150 KD. Human IgG1
A2633 Anti-OX2R / CD200R1 Anti-OX2R / CD200R1 is a monoclonal antibody targeting CD200. It exhibited potential in regulating tissue inflammation during skin wound healing. MW :146.58 KD. Human IgG4SP
A2889 Imgatuzumab (Anti-ERBB1 / EGFR / HER1) Imgatuzumab (Anti-ERBB1 / EGFR / HER1) is a glycoengineered monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. MW: 145.28 KD. Human IgG1
A3145 Anti-MERS (D12) Anti-MERS (D12) is a human monoclonal antibody that targets to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD). It is useful in inhibiting virus invasion into host cells. MW :150 KD. Human IgG1
A2634 Bleselumab (Anti-TNFRSF5 / CD40) Bleselumab (Anti-TNFRSF5 / CD40) is a human monoclonal antibody (mAb) targeting human CD40. It has the potential to prevents organ transplant rejection. MW :150 KD. Human IgG4PE
A2890 Laprituximab (Anti-ERBB1 / EGFR / HER1) Laprituximab (Anti-ERBB1/ EGFR / HER1) is a humanized IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) with anti-tumor activity. MW: 145.2 KD. Human IgG1
A3146 Anti-Spike S1 (CR3022) Anti-Spike RBD Antibody (CR3022) is an antibody specifically targeting and binding to coronavirus S protein. It showed excellent and significantly better activity in coronaviruses diseases. MW :150 KD. Human IgG1
A2635 Sotigalimab (Anti-TNFRSF5 / CD40) Sotigalimab (Anti-TNFRSF5 / CD40) is an agonistic monoclonal antibody targeting CD40. It can be used for the research of metastatic pancreatic adenocarcinoma.MW :144.54 KD. Human IgG1
A2891 Matuzumab (Anti-ERBB1 / EGFR / HER1) Matuzumab (anti-ERBB1/ EGFR / HER1) is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody that blocks EGFR activation, downstream signalling, and inhibits tumor growth. MW: 145.9 KD. Human IgG1
A3147 Anti-AA2AR / Adenosine A2aR (3F6-9G5) Anti-AA2AR / Adenosine A2aR (3F6-9G5) is a monoclonal antibody targeting A2A adenosine receptor. It may be an attractive target for research studies or treatments of insomnia, pain, depression, and Parkinson's disease. MW :146.66 KD. Human IgG1
A2636 Dacetuzumab (Anti-TNFRSF5 / CD40) Dacetuzumab (Anti-TNFRSF5 / CD40) is a humanized IgG1, monoclonal antibody targeting CD40. Ithas anti-lymphoma activity and can be used for multiple myeloma research. MW :150 KD. Human IgG1
A2892 Golimumab (Anti-TNFSF2 / TNFa) Golimumab (Anti-TNFSF2 / TNFa) is a human monoclonal antibody directed against the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-a) with immunosuppressive activity. MW: 146.94 KD. Human IgG1
A3148 Anti-BTN1A1 (ICT-01) Anti-BTN1A1 (ICT-01-N297A) is a humanized monoclonal antibody targeting BTN1A1. It can be used in treatment of advanced solid tumors. MW :146.2 KD. Human IgG1
A2637 Anti-CD47 (CC-90002) Anti-CD47 (CC-90002) is a humanized monoclonal antibody (mAb) targeting CD47. It can be used for the research of hematologic malignancies and solid tumors. MW :150 KD. Human IgG4SP
A2893 Pimurutamab (Anti-ERBB1 / EGFR / HER1) Pimurutamab (Anti-ERBB1 / EGFR / HER1) is a glycoengineered humanized monoclonal antibody against epidermal growth factor receptor (EGFR) potential antineoplastic activity. MW: 144.92 KD. Human IgG1
A3149 Anti-BTN1A1 (ICT-01-N297A) Anti-BTN1A1 (ICT-01) is a humanized monoclonal antibody targeting BTN1A1. It can be used in treatment of advanced solid tumors. MW :146.2 KD. Human IgG1
A2638 Labetuzumab (Anti-CEACAM5 / CEA / CD66e) Labetuzumab (Anti-CEACAM5 / CEA / CD66e) is a humanised monoclonal antibody targeting carcinoembryonic antigen (CEA). It inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy. MW :145.36 KD. Human IgG1
A2639New Anti-CEACAM6 / CD66c (NEO-201) Anti-CEACAM6 / CD66c (NEO-201) is a humanized IgG1 monoclonal antibody that targets of CEACAM family. It enhances natural killer cell cytotoxicity against tumor cells. MW :145.48 KD. Human IgG1
A2895 Zalutumumab (Anti-ERBB1 / EGFR / HER1) Zalutumumab (Anti-ERBB1 / EGFR / HER1) is a fully human IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) with potential antineoplastic activity. MW: 146.52 KD. Human IgG1
A2640 Anti-CHI3L1 Anti-CHI3L1 is a monoclonal antibody targeting Chitinase 3–like 1 (CHI3L1). It proves a promising therapy for pulmonary metastasis and progression. MW :147.04 KD. Human IgG1
A2641 Anti-DCBLD2 / ESDN (FA19-1) Anti-DCBLD2 / ESDN (FA19-1) is a polyclonal antibody that targets the DCBLD2. It inhibits tumor metastasis in lung adenocarcinoma (LUAD). MW :146.84 KD. Human IgG1
A2897 Ifabotuzumab (Anti-EphA3) Ifabotuzumab (Anti-EphA3) is a monoclonal antibody against EphA3. MW: 145.28 KD. Human IgG1
A2642 Zolbetuximab (Anti-CLDN18.2) Zolbetuximab (Anti-CLDN18.2) is a monoclonal antibody targeting Claudin-18.2. It can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors. MW :150 KD. Human IgG1
A2898 Hersintuzumab (Anti-ERBB2 / HER2 / CD340) Hersintuzumab (Anti-ERBB2 / HER2 / CD340) is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2), extracellular domains I–II, with antitumor activity in ovarian cancer. MW: 144.26 KD. Human IgG1
A3154 Anti-CDH17 / Cadherin-17 (10C12) Anti-CDH17 / Cadherin-17 (10C12) is a humanized monoclonal antibody targeting Cadherin-17 (CDH17), a prominent cancer biomarker. It has growth inhibitory effect on liver and stomach tumour cells. It can be used as therapeutics for treating lung metastasis of hepatocellular carcinoma (HCC). MW :143.68 KD. Human IgG1
A2643 Anti-CLDN6 (IMAB027) Anti-CLDN6 (IMAB027) is a fully humanized antibody targeting CLDN6. It gets conjugated to monomethyl auristatin E( MMAE) resulting in the potential therapeutic CLDN6–23-ADC. It exhibits antitumor efficacy in ovarian epithelial carcinomas.MW :144.42 KD. Human IgG1
A2899 Margetuximab (Anti-ERBB2 / HER2 / CD340) Margetuximab (Anti-ERBB2 / HER2 / CD340) is a Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. MW: 146.1 KD. Human IgG1
A3155 Anti-CDH17 / Cadherin-17 (PTA001_A4) Anti-CDH17 / Cadherin-17 (PTA001_A4) is a humanized monoclonal antibody targeting Cadherin-17 (CDH17), a prominent cancer biomarker. It has growth inhibitory effect on tumour cells. It can be used as therapeutics for treating various cancers, including colorectal cancer. MW :149.12 KD. Human IgG1
A2644 Cabiralizumab (Anti-CSF1R / M-CSFR / CD115) Cabiralizumab (Anti-CSF1R / M-CSFR / CD115) is an monoclonal antibody (MAb) targeting CSF1R. It can be used in the research of rheumatoid arthritis (RA), melanoma, kidney cancer, or non-small cell lung cancer. MW :146.3 KD. Human IgG4SP
A2900 Timigutuzumab (Anti-ERBB2 / HER2 / CD340) Timigutuzumab (Anti-ERBB2 / HER2 / CD340) is a humanized immunoglobulin that targets the extracellular domain of the human epidermal growth factor receptor 2 (ErbB2, also known as HER2). Timigutuzumab can be used for cancer research. MW: 150 KD. Human IgG1
A2901 Barecetamab (Anti-ERBB3 / HER3) Barecetamab (Anti-ERBB3/HER3) is a fully human antibody directed against the receptor tyrosine-protein kinase erbB-3 (ErbB3; HER3) with antineoplastic activity. It has the potential to be used in research on recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). MW: 137.96 KD. Human IgG1
A3157 Anti-CLDN6 (AB3-7) Anti-CLDN6 (AB3-7) is a monoclonal antibody targeting the tumor-associated antigen (TAA) Claudin 6 (CLDN6). It has an antitumor activity and can be used in treatment of various cancers. MW :145.0 KD. Human IgG1
A2646 Anti-CXCL9 Anti-CXCL9 is an antibody targeting CXCL9 chemokine. It has the potemtial of inhibiting inflammation. MW :150 KD. Human IgG1
A2902 Lumretuzumab (Anti-ERBB3 / HER3) Lumretuzumab (Anti-ERBB3 / HER3) is an immunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. MW: 147.16 KD. Human IgG1
A3158 Anti-CLDN6 (AB1-11) Anti-CLDN6 (AB1-11) is a monoclonal antibody targeting the tumor-associated antigen (TAA) Claudin 6 (CLDN6). It enhances malignant potentials and drug resistance of cervical ADC and can provide a new therapeutic strategy for uterine cervical adenocarcinoma. MW :144.66 KD. Human IgG1
A2647 Anti-CXCR5 / CD185 (SAR113244) Anti-CXCR5 / CD185 (SAR113244) is a humanized monoclonal antibody that specifically targets CXCR5. It can be used in the treatment of arthritis, autoimmune diseases, inflammatory diseases, graft rejection, and cancer . MW :144.1 KD. Human IgG1
A2903 Anti-VEGFR2 / KDR / CD309 (Imclone 6.64) Anti-VEGFR2 / KDR / CD309 (Imclone 6.64) is a monoclonal antibody targated against vascular endothelial growth factor receptor-2 (VEGFR2) with anti-angiogenesis and anti-tumour activity. MW: 145.4 KD. Human IgG1
A3159 Datopotamab (Anti-TROP2) Datopotamab (Anti-TROP2) is an antibody targeting to TROP2. It demonstrates potent antitumor activity and can be used in non-small cell lung cancer (NSCLC) research. MW :145.16 KD. Human IgG1
A2648 Anti-DC-SIGN / CD209 Anti-DC-SIGN / CD209 is a humanized monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients. ME :146.62 KD. Human IgG1
A2904 Anti-CD19 (Immunomedics hA19) Anti-CD19 (Immunomedics hA19) is a humanized IgG1kappa monoclonal antibody targated against CD19 with the potential to treat autoimmune diseases. MW: 147.32 KD. Human IgG1
A3160 Loncastuximab (Anti-CD19) Loncastuximab (Anti-CD19) is a monoclonal antibody targeting CD19. It shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). MW :144.38 KD. Human IgG1
A2905 Abelacimab (Anti-F11 / Factor XI) Abelacimab (Anti-F11 / Factor XI) is a human anti-factor XI (FXI) monoclonal antibody with potential anti-thrombotic activity. MW: 144.36 KD. Human IgG1
A3161 Gemtuzumab (Anti-Siglec-3 / CD33) Gemtuzumab (Anti-Siglec-3 / CD33) a monoclonal antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). It can be used for the research of acute myeloid leukemia.MW :145.22 KD. Human IgG4SP
A2650 Anti-TNFRSF21 / DR6 / CD358 Anti-TNFRSF21 / DR6 / CD358 is a humanized monoclonal antibody that specifically targets TNFRSF21. It can be used in treatment of cancer. MW :150 KD. Human IgG1
A2906 Anti- FcRL5 / IRTA2 / CD307e (DFRF4539A) Anti- FcRL5 / IRTA2 / CD307e (DFRF4539A) is a monoclonal antibody directed against Fc receptor homolog 5 (FcRH5, IFGP5, BXMAS1, CD307, IRTA2) with potential antineoplastic activity. MW: 144.68 KD. Human IgG1
A3162 Ozuriftamab (Anti-ROR2) Ozuriftamab (Anti-ROR2) is a naked human IgG1 kappa antibody targeting receptor tyrosine kinase-like orphan receptor 2 ROR.It has antineoplastic activity and can be used in research of head and neck squamous cell cancer (HNSCC) Human IgG1
A2651 Citatuzumab (Anti-EpCAM / TROP1 / CD326) Citatuzumab (Anti-EpCAM / TROP1 / CD326) is a recombinant immunotoxin that composed of humanized monoclonal antibody targeting EpCAM. It has antitumor activity and can be used in treatment of cancer. MW :145.4 KD. Human IgG1
A3163 Lifastuzumab (Anti-SLC34A2) Lifastuzumab (Anti-SLC34A2) is a monoclonal antibody targeting SLC34A2 (sodium phosphate 2 transporter(NaPi2b)). It has anticancer activity and can be used in research of ovarian cancer (OC). Human IgG1
A2652 Sibrotuzumab (Anti-FAP) Sibrotuzumab (Anti-FAP) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). It can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC). MW :148.66 KD. Human IgG1
A2908 Anti-DDR1 / CD167a (Imperial College anti-DDR1) Anti-DDR1 / CD167a (Imperial College anti-DDR1) is a monoclonal antibody againts discoidin domain receptor 1 with potential anti-tumor activity. MW: 143.32 KD. Human IgG1
A3164 Serclutamab (Anti-ERBB1 / EGFR / HER1) Serclutamab (Anti-ERBB1 / EGFR / HER1) is a monoclonal antibody targeting epidermal growth factor receptor (EGFR). It can be used in research of advanced solid tumors for advanced glioblastoma. MW :150 KD. Human IgG1
A2653 Anti-FGF19 (1A6) Anti-FGF19 (1A6) is a humanized monoclonal antibody that specifically targets FGF19. It has antitumoe activities and can used in the treatment of hepatocellular carcinoma (HCC). MW :145.2 KD. Human IgG1
A2909 Anti-FGFR1 / CD331 Anti-FGFR1 / CD331 is a monoclonal antibody againts human fibroblast growth factor receptor 1. MW: 150 KD. Human IgG1
A3165 Anti-TfR (Jr-141) Anti-TfR (Jr-141), is an antibody targeting human transferrin receptor (hTfR). It can be used in treatment of patients with mucopolysaccharidosis II (MPS II) and CNS disorders. MW :146.02 KD. Human IgG1
A2654 Anti-Fibronectin (L19-TNF) Anti-Fibronectin (L19-TNF) is a monoclonal antibody targeting fibronectin ED-B and interleukin 12. it can be used in treatment of advanced soft-tissue sarcoma. MW :144.14 KD. Human IgG4SP
A2910 Anti-TSPAN8 Anti-TSPAN8 is a monoclonal IgG1 antibody (mAb) directed against Co-029, a membrane protein of the family of tetraspanins (TSPAN8 or TM4SF3). MW: 145.94 KD. Human IgG1
A3166 Anti-MSPR / RON / CD136 (H5B14) Anti-MSPR / RON / CD136 (H5B14) is a neutralizing human monoclonal antibody-drug conjugate that targets RON binding to its ligand, macrophage-stimulating protein (MSP). It has an strong potential in treatment of chronic liver inflammation and also in autoimmune diseases. MW :156.7 KD. Human IgG1
A2655 Crotedumab (Anti-GCGR) Crotedumab (Anti-GCGR) is a fully human IgG4 monoclonal antibody targeting glucagon receptor (GCGR). It can be used for the research of diabetes. MW :146.98 KD. Human IgG4SP
A2911 Radretumab (Anti-Fibronectin) Radretumab (anti-fibronectin) is a monoclonal antibody that targets the extra-domain B fibronectin present in the extracellular matrix surrounding newly formed blood vessels in solid tumors. MW: 144.2 KD. Human IgG1
A3167 Anti-PVR / CD155 (Ntx1088) Anti-PVR / CD155 (Ntx1088) is a first-in-class potent monoclonal antibody targeting poliovirus receptor. It can be used in treatment of patients with locally advanced and metastatic solid tumors. MW :145.86 KD. Human IgG1
A2656 Anti-CSF3R / G-CSFR Anti-CSF3R / G-CSFR is an antibody that targets G-CSF. I t can be used in the research of inflammatory diseases. MW :150 KD. Human IgG4SP
A2912 Pelgifatamab (Anti-FOLH1 / PSMA) Pelgifatamab (anti-FOLH1 / PSMA) is an immunoglobulin G1-kappa monoclonal antibody targated against FOLH1 (folate hydrolase, prostate-specific membrane antigen, psma). MW: 146.24 KD. Human IgG1
A3168 Anti-CD98 (Ign523) Anti-CD98 (Ign523) is a humanized monoclonal antibody targeting CD98. It can be used in patients with relapsed or refractory acute myeloid leukemia (AML). MW :145.66 KD. Human IgG1
A2657 Anti-GPR49 / LGR5 (BNC101) Anti-GPR49 / LGR5 (BNC101) is a human specific monoclonal antibody targeting the GPCR-LGR5. It can be used in the treatment of metastatic colorectal cancer (CRC). MW :150 KD. Human IgG1
A2913 Iparomlimab (Anti-PDCD1 / PD-1 / CD279) Iparomlimab (Anti-PDCD1 / PD-1 / CD279) is a human IgG4κ monoclonal antibody targated against PD-1/CD279/PDCD1. Iparomlimab can be used for oncology research. MW: 144.18 KD. Human IgG4SP
A3169 Anti-TREM2 (Py314) Anti-TREM2 (Py314) is a humanized monoclonal antibody that specifically targets the triggering receptor expressed on myeloid cells 2 (TREM2). It can be used in cancer research and in treatment of variety of solid tumor types. MW :145.24 KD. Human IgG1
A2914 Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4) with potential immunostimulatory activity. MW: 144.18 KD. Human IgG2SA
A3170 Tidutamab (Anti-CD3 & SSTR2) Tidutamab (Anti-CD3 & SSTR2) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). It can be used in neuroendocrine tumors (NETs) and small cell lung cancer (SCLC). MW :147.36 KD. Human IgG1
A2659 Anti-Haptoglobin Anti-Haptoglobin is an antibody targeting the human haptoglobin (HP). It can be used for immunoblotting after isoelectric focusing to determine Hp alpha subtypes. MW :150 KD. Human IgG1
A2915 Anti-ERG Anti-ERG is a monoclonal IgG1 antibody (mAb) directed against the proto-oncogene ETS-related gene (ERG). It has the potential to treat prostate cancer, Ewing's sarcoma, acute myeloid leukemia, endothelial cancer, and colon cancer. MW: 145.4. Human IgG1
A3171 Anti-ADAM9 (Imgc936) Anti-ADAM9 (Imgc936) is a humanized antibody targeting the ADAM metallopeptidase domain 9 (ADAM9). It is a therapeutic candidate for the treatment of various cancers including non-small cell lung, pancreatic, gastric, breast, ovarian, and colorectal cancer. MW :147.66 KD. Human IgG1
A2660 Seribantumab (Anti-ERBB3 / HER3) Seribantumab (Anti-ERBB3 / HER3) is a fully human IgG2 monoclonal antibody that targets HER3. It inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models. MW : 143.14 KD. Human IgG2SA
A2916 Anti-GD2 (EMD 273063) Anti-GD2 (EMD 273063) is a humanized immunoglobulin G1 (IgG1) anti-GD2 monoclonal antibody directed against the human pro-inflammatory cytokine interleukin (IL)-2 with potential antineoplastic and immunomodulatory activities. MW: 144.84 KD. Human IgG1
A3172 Cantuzumab (Anti-CanAg) Cantuzumab (Anti-CanAg) humanized monoclonal antibody targeting CanAg. It has broad antitumor efficacy in colon cancer cells. MW :147.02 KD Human IgG1
A2661 Ficlatuzumab (Anti-HGF / SF) Ficlatuzumab (Anti-HGF / SF) is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). It inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion and can be used to treat head and neck squamous cell carcinoma (HNSCC). MW :150 KD. Human IgG1
A2662 Emibetuzumab (Anti-HGFR / c-Met) Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD. Human IgG4SP
A2663 Anti-IDO2 Anti-IDO2 is a monoclonal antibody targeting Indoleamine 2,3-dioxygenase 2 (IDO2). It exhibits potency that ameliorates arthritis and autoimmune disease. MW :151.06 KD. Human IgG1
A2664 Rontalizumab (Anti-IFNa1) Rontalizumab (Anti-IFNa1) is a humanized IgG1 monoclonal antibody targets IFN-α. It can be used for the research of systemic lupus erythematosus. MW :150 KD. Human IgG1
A2920 Latozinemab (Anti-Sortilin / SORT1) Latozinemab (anti-Sortilin / SORT1) is a recombinant humanized anti-Sortilin monoclonal antibody. Latozinemab has the potential for progranulin gene (GRN) mutations causative of frontotemporal dementia (FTD) (FTD-GRN) research. MW: 146.28 KD. Human IgG1
A2665 Anrukinzumab (Anti-IL-13) Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 KD. Human IgG1
A2921 Lemzoparlimab (Anti-CD47) Lemzoparlimab (anti-CD47) is a human monoclonal antibody targeting the human cell surface antigen CD47 with potential phagocytosis-inducing and antineoplastic activities. MW: 145.58 KD. Human IgG4SP
A2666 Anti-IL-13Ra2 / CD213a2 Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD. Human IgG1
A2922 Lilotomab (Anti-TSPAN26 / CD37) Lilotomab (Anti-TSPAN26 / CD37) is a murine immunoglobulin G1 (IgG1) monoclonal antibody directed against the CD37 antigen with potential antineoplastic activity. MW: 145.64 KD. Human IgG1
A2667 Imsidolimab (Anti-IL-1RL2 / IL-36R) Imsidolimab (Anti-IL-1RL2 / IL-36R) is a high-affinity, humanized monoclonal antibody targeting IL-36R. It has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases. MW :150 KD. Human IgG4SP
A2923 Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD. Human IgG1
A2668 Etokimab (Anti-IL-33) Etokimab (Anti-IL-33) is a humanized monoclonal antibody that targets IL-33. It can be used for the research of atopic dermatitis. MW :146.56 KD. Human IgG1
A2924 Lodelcizumab (Anti-PCSK9) Lodelcizumab is a human monoclonal antibody targated against proprotein convertase subtilisin/kexin type 9 (PCSK9) with the potential to be used in research on hypercholesterolemia. MW: 145.66 KD. Human IgG1
A2669 Lusvertikimab (Anti-IL-7Ra / CD127) Lusvertikimab (Anti-IL-7Ra / CD127) is a humanized monoclonal antibody targeting IL7R. It has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research. MW :145.64 KD. Human IgG4SP
A2925 Anti-GPR64 / ADGRG2 Anti-GPR64 / ADGRG2 is a monoclonal antibody (mAb) against G protein-coupled receptor 64 isoform 4 (anti-GPR64) with potential anti-tumour activity. MW: 146.1. Human IgG4SP
A2670 Anti-CXCL8 / IL-8 (HuMax-IL8) Anti-CXCL8 / IL-8 (HuMax-IL8) is a monoclonal antibody targeting CXCL8. It has strong antitumor effect. MW :144.94 KD. Human IgG1
A2926 Lonigutamab (Anti-IGF1R / CD221) Lonigutamab (hz208F2-4) is a humanized monoclonal antibody against the insulin-like growth factor-1 receptor (IGF-1R) with the potential to treat thyroid eye disease (TED). MW: 146.26 KD. Human IgG1
A2671 Anti-Lewis Y (MB 311) Anti-Lewis Y (MB 311) is a fully humanized monoclonal antibody recognizing the tumor-associated antigen Lewis Y. It represents an attractive target for cancer immunotherapy and can be used in treatment of breast cancer. MW 146.38 KD. Human IgG1
A2927 Losatuxizumab (Anti-ERBB1 / EGFR / HER1) Losatuxizumab (ABT-806) is a human monoclonal antibody against EGFR with anti-tumour activity. MW: 144.8 KD. Human IgG1
A2672 Anti-MAGEA3 Anti-MAGEA3 is an antibody that targets MAGE-A. It can be used in the treatment of metastatic cancer treatment. MW :145.56 KD. Human IgG1
A2928 Anti-Hepcidin / HAMP (Ludwig-Maximilians U. anti_Hepsin) Anti-Hepcidin / HAMP (Ludwig-Maximilians U. anti-Hepsin) is a monoclonal antibody (mAb) that neutralizing hepcidin and results in transferrin-mediated iron transport. MW: 142.68. Human IgG1
A2673 Anetumab (Anti-Mesothelin) Anetumab (Anti-Mesothelin) is an antibody targeting mesothelin (MSLN). It can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC) and can be used for the research of malignant tumor. MW :143.8 KD. Human IgG1
A2929 Anti-KID3 Anti-KID3 is a monoclonal antibody (MAb) directed against KID3, a carbohydrate epitope found in the colon and several forms of cancer. MW: 147.04 KD. Human IgG1
A2674 Oregovomab (Anti-MUC16) Oregovomab (Anti-MUC16) is a humanized monoclonal antibody that targets MUC16. It can be used in treatment of ovarian, pancreatic, breast, and lung cancers. MW 150 KD. Human IgG1
A2930 Anti-HGF / SF (TAK-701) Anti-HGF / SF (TAK-701) is a humanized monoclonal antibody directed against human hepatocyte growth factor (HGF) with potential antineoplastic activity. It reverses gefitinib resistance in non-small-cell lung cancer. MW: 145.04 KD. Human IgG1
A2675 Sofituzumab (Anti-MUC16) Sofituzumab (Anti-MUC16) is a humanized recombinant V-kappa antibody targeting MUC16. It can be used for the research of ovarian cancer. MW 144.7 KD. Human IgG1
A2676 Landogrozumab (Anti-GDF8 / Myostatin) Landogrozumab (Anti-GDF8 / Myostatin) is an humanized monoclonal antibody targeting myostatin. It effectively improves muscle volume, hand grip strength and function and can be used for the research of muscle wasting disease. MW :150 KD. Human IgG4SP
A2932 Anti-HGFR / c-Met (SAIT301) Anti-HGFR / c-Met (SAIT301) is a humanized monoclonal antibody targeting the alpha chain of the extracellular domain of the human hepatocyte growth factor receptor (HGFR or c-Met) with potential antineoplastic activity. MW: 146.0 KD. Human IgG1
A2677 Trevogrumab (Anti-GDF8 / Myostatin) Trevogrumab (Anti-GDF8 / Myostatin) is a monoclonal antibody targeting GDF8. It is used in studies of sarcopenia, including wasting atrophy, chronic diseases, and changes in food and nutritional intake. MW :150 KD. Human IgG4SP
A2933 Anti-Amyloid Beta (Merck anti-Amyloid beta 19.3) Anti-Amyloid Beta (Merck anti-Amyloid beta 19.3) is a human monoclonal antibody targeting beta-amyloid with the potential to treat Alzheimer’s disease. MW: 145.22 KD. Human IgG1
A2678 Fulranumab (Anti-NGF / bNGF) Fulranumab (Anti-NGF / bNGF) is a human IgG2 monoclonal antibody targeting nerve growth factor (NGF). It can be used for the research of pain. MW :145.37 KD. Human IgG2SA
A2679 Tanezumab (Anti-NGF / bNGF) Tanezumab (Anti-NGF / bNGF) is a human IgG2 monoclonal antibody targeting nerve growth factor (NGF). It can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia. MW :150 KD. Human IgG1
A2935 Mirzotamab (Anti-B7-H3 / CD276) Mirzotamab (Anti-B7-H3 / CD276) is a human IgG1κ monoclonal antibody targeting CD276/B7-H3. Mirzotamab is used to produce Mirzotamab clezutoclax antibody drug conjugate (ADC). MW: 144.86 KD. Human IgG1
A2680 Ozanezumab (Anti-RTN4 / NOGO) Ozanezumab (Anti-RTN4 / NOGO) is a monoclonal antibody targeting Nogo-A (neurite outgrowth inhibitor A). It can be used in amyotrophic lateral sclerosis (ALS) and multiple sclerosis research. MW :150 KD. Human IgG1
A2936 Modotuximab (Anti-ERBB1 / EGFR / HER1) Modotuximab (Anti-ERBB1 / EGFR / HER1) is a recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. MW: 146.6 KD. Human IgG1
A2681 Brontictuzumab (Anti-NOTCH1) Brontictuzumab (Anti-NOTCH1) is a monoclonal antibody that targets Notch1 signal. It inhibits tumor cell proliferation and can be used in the research of leukemia and lymphoma. MW :150 KD. Human IgG2SA
A2937 Anti-ICOS / CD278 (MEDI-570) Anti-ICOS/CD278 (MEDI-570) is a Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278) with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat non-Hodgkin lymphomas. MW: 146.82 KD. Human IgG1
A2682 Vesencumab (Anti-NRP1 / VEGF165R / CD304) Vesencumab (Anti-NRP1 / VEGF165R / CD304) is an IG1 antibody targeting neuropilin-1 (NRP-1). It has anti-angiogenic and anti-neoplastic activities and can be used in the research of metastatic solid tumors, including ovarian cancer and Diabetic macular edema (DME). MW :150 KD. Human IgG1
A2938 Anti-IFNg (AMG 811) Anti-IFNg (AMG 811) is a human monoclonal antibody (IgG1 isotype) that selectively targets human IFNgamma 7. It has potential to treat systemic lupus erythematosus (SLE). MW: 144.36 KD. Human IgG1
A2683 Tavolixizumab (Anti-TNFRSF4 / OX40 / CD134) Tavolixizumab (Anti-TNFRSF4 / OX40 / CD134) is a human monoclonal antibody targeting TNFRSF4 (TNF receptor superfamily member 4) and OX40. It can be used in cancer immunology research. MW :146.36 KD. Human IgG1
A2939 Ligelizumab (Anti-IgE) Ligelizumab (anti-IgE) is a humanized high-affinity monoclonal anti-IgE antibody with the potential to be used in research on chronic spontaneous urticarial. MW: 146.6 KD. Human IgG1
A2684 Anti-PDGFC / VEGFE Anti-PDGFC / VEGFE is a monoclonal antibody targeting PDGF-CC. It can be used in the research of cancer, fibrosis and neuropathologies. MW :145.9 KD. Human IgG1
A2940 Talizumab (Anti-IgE) Talizumab (anti-IgE) is a humanized monoclonal antibody against immunoglobulin E (IgE) with the potential to treat food allergies. MW: 146.56 KD. Human IgG1
A2941 Naptumomab (Anti-TPBG) Naptumomab (Anti-TPBG) is a monoclonal antibody directed towards the tumor-associated oncofetal trophoblast glycoprotein antigen 5T4 with immunomodulating and antineoplastic activities. MW: 145.18 KD. Human IgG1
A2686 Anti-PSCA (AGS-1C4D4) Anti-PSCA (AGS-1C4D4) is a fully human IgG1k monoclonal antibody directed against the human prostate stem cell antigen (PSCA). Anti-PSCA inhibits tumor formation and metastasis in orthotopic models of pancreatic cancer. MW : 145.42 kD. Human IgG1
A2942 Figitumumab (Anti-IGF1R / CD221) Figitumumab (Anti-IGF1R / CD221) is a human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. MW: 146.0 KD. Human IgG1
A2687 Anti-PVRIG (GSK4381562) Anti-PVRIG (GSK4381562) is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 150 kD. Human IgG1
A2688 Anti-AGER / RAGE (XT-M4) Anti-AGER / RAGE (XT-M4) is a humanized anti-RAGE antibody with potential to treat acute and chronic inflammatory conditions. MW: 145.14 KD. Human IgG1
A2944 Nimotuzumab (Anti-ERBB1 / EGFR / HER1) Nimotuzumab (Anti-ERBB1 / EGFR / HER1) is a humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. MW: 147.58 KD. Human IgG1
A2689 Anti-RSPO1 Anti-RSPO1 is a monoclonal antibodies against R-spondin1 gene (RSPO1) with potential anti-tumor activity . MW: 150 KD. Human IgG1
A2945 Anti-IGF2 (DX-2647) Anti-IGF2 (DX-2647) is a human monoclonal antibody against insulin-like growth factor-II (IGF-II) with anti-tumor  and anti-proliferative activities. MW: 145.78 KD. Human IgG1
A2690 Setrusumab (Anti-SOST / Sclerostin) Setrusumab (Anti-SOST / Sclerostin) is a fully humanized monoclonal antibody directed against sclerostin. Setrusumab effectively improves bone strength and has the potential to be used in the research of Osteogenesis Imperfecta (OI). MW :143.44 kD. Human IgG2SA
A2946 Anti-IL-10 (BT-063) Anti-IL-10 (BT-063) is a human monoclonal antibody directed against the human interleukin 10 (IL-10). It has the potential to be used in the treatment of systemic lupus erythematosus (SLE). MW: 145.74 KD. Human IgG1
A2691 Anti-SIRPa / CD172a Anti-SIRPa / CD172a is an immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. MW : 147.06 kD. Human IgG4SP
A2947 Briakinumab (Anti-IL-12) (IL-12a & IL-12b) Briakinumab (anti-IL-12) (IL-12a & IL-12b) is a human monoclonal antibody directed against the human interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. It has the potential to be used in the treatment of Crohn's disease. MW: 143.86 KD. Human IgG1
A2692 Gosuranemab (Anti-Tau) Gosuranemab (Anti-Tau) is a humanized monoclonal antibody against the extracellular N-terminal of tau in the interstitial fluid (ISF) and CSF released by neurons. It has the potential for research of alzheimer’s disease (AD). MW : 150 kD. Human IgG4SP
A2948 Nipocalimab (Anti-FcRn) (FCGRT & B2M) Nipocalimab (anti-FcRn) (FCGRT & B2M) is a fully human monoclonal antibody that targets the neonatal crystallizable fragment receptor (FcRn) with potential immunomodulating activity. MW: 142.12 KD. Human IgG1
A2693 Semorinemab (Anti-Tau) Semorinemab (Anti-Tau) is a humanized IgG4 monoclonal antibody that targets the N-terminal domain of tau (amino acid residues 6-23). Semorinemab has the potential to be used in research on Alzheimer's disease. MW : 150 kD. Human IgG4SP
A2949 Cendakimab (Anti-IL-13) Cendakimab (anti-IL-13) is a humanized, recombinant monoclonal antibody against the interleukin-13 (IL-13) molecule with the potential to treat allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). MW: 146.44 KD. Human IgG1
A2694 Anti-TGFb1 (SRK181) Anti-TGFb1 (SRK181) is a monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 with potential antineoplastic activity. MW : 150 kD. Human IgG4SP
A2950 Dectrekumab (Anti-IL-13) Dectrekumab (anti-IL-13) is a humanized monoclonal antibody that targets interleukin-13 (IL-13). It has the potential to be used in inflammation and immunology-related research. MW: 146.16 KD. Human IgG1
A2951 Anti-IL-13 (GSK 679586) Anti-IL-13 (GSK 679586) is a humanized monoclonal IgG1 antibody against interleukin-13 (IL-13). It has the potential to treat chronic spontaneous urticaria. MW: 148.38 KD. Human IgG1
A2696 Anti-TLR3 / CD283 (CNTO5429) Anti-TLR3 / CD283 (CNTO5429) is a novel antibody that binds to the extracellular domain of TLR3 and inhibit poly(I:C)-induced inflammation. MW: 145.3 KD. Human IgG2SA
A2952 Anti-IL-13 (H2L6) Anti-IL-13 (H2L6) is a humanized antibody against interleukin-13 (IL-13). MW: 146.16 KD. Human IgG1
A2697 Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD. Human IgG1
A2953 Anti-IL-13 (IMA-026) Anti-IL-13 (IMA-026) is a humanized IgG1 antibody targated against interleukin 13 (IL-13) with the potential to treat chronic spontaneous urticaria. MW: 146.88 KD. Human IgG1
A2698 Anti-TYRO3 (ELB031) Anti-TYRO3 (ELB031) is a monoclonal antibody that targets TYRO3 and MERTK. Human IgG1
A2954 Lebrikizumab (Anti-IL-13) Lebrikizumab (anti-IL-13) is an humanized IgG4 monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. MW: 145.8 KD. Human IgG4SP
A2699 Timolumab (Anti-AOC3 / VAP1) Timolumab (Anti-AOC3 / VAP1) is a fully human monoclonal antibody directed against vascular adhesion protein-1 (VAP-1). Timolumab has the potential to be used in research on chronic inflammatory diseases. MW : 150 kD. Human IgG4SP
A2955 Anti-IL-13 (M1295) Anti-IL-13 (M1295) is a humanized antibody against interleukin-13 (IL-13). MW: 145.8 KD. Human IgG1
A2956 Nofazinlimab (Anti-PDCD1 / PD-1 / CD279) Nofazinlimab (anti-PDCD1/ PD-1 / CD279) is a humanised IgG4 monoclonal antibody targeting PD-1. Nofazinlimab has the potential to be used in unresectable hepatocellular carcinoma (uHCC) research. MW: 145.08 KD. Human IgG4SP
A2701 Anti-Complement C2 (ARGX-117) Anti-Complement C2 (ARGX-117) is a monoclonal antibody that inhibits complement factor C2. It inhibits complement in a disease model for multifocal motor neuropathy. MW: 146.12 kD. Human IgG1
A2702 Anti-GPR20 (DS-6157) Anti-GPR20 (DS-6157) is a monoclonal antibody directed against the G protein-coupled receptor 20 (GPR20) with potential antineoplastic activity. MW : 150 kD. Human IgG1
A2958 Anti-IL-15 (DISC0280) Anti-IL-15 (DISC0280) is a human monoclonal antibody targated againts Interleukin-15 (IL-15). MW: 145.62 KD. Human IgG1
A2703 Bapotulimab (Anti-ILDR2) Bapotulimab (Anti-ILDR2) is a fully human immunoglobulin G2 (IgG2) monoclonal antibody against the immune checkpoint immunoglobulin-like domain containing receptor 2 (ILDR2; Chromosome 1 Open Reading Frame 32; C1orf32), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 145.24 kD. Human IgG2SA
A2959 Anti-IL-18 (ABT-325) Anti-IL-18 (ABT-325) is a humanized monoclonal antibody targeted against interleukin-18 (IL-18) with the potential to treat autoimmune diseases. MW: 146.28 KD. Human IgG1
A2704 Anti-Integrin aVb6 (ITGAV & ITGB6) (STX-100) Anti-Integrin aVb6 (ITGAV & ITGB6) (STX-100) is a humanized monoclonal antibody directed against the alpha v beta 6 (αvβ6) integrin. It has a potential to be used in research on Idiopathic Pulmonary Fibrosis (IPF). MW : 144.88 kD. Human IgG1
A2960 Anti-IL-1b (CDP484) Anti-IL-1b (CDP484) is an antibody targated against Interleukin-1beta (IL-1b), a cytokine that initiates inflammatory cascades. MW: 145.74 KD. Human IgG1
A2961 Anti-F8 / Factor VIII Anti-F8 / Factor VIII is a monoclonal IgG anti-factor VIII antibody that hydrolyzes FVIII in acquired hemophilia. MW: 145.14 KD. Human IgG1
A2706 Anti-CXCR3 / GPR9 / CD183 Anti-CXCR3 / GPR9 / CD183 is a monoclonal antibody binds to Chemokine (C-X-C motif) receptor 3 (CXCR3, also known as G protein-coupled receptor 9 (GPR9)) . It has the potentially to be used in the treatment of diabetes mellitus type I (T1D). MW: 146.38 KD. Human IgG1
A2962 Melrilimab (Anti-IL-1RL1 / ST2 / IL-33R) Melrilimab (anti-IL-1RL1/ ST2 / IL-33R) is an anti-ST2 (IL-1RL) monoclonal antibody targeting the IL-33 receptor. Melrilimab has the potential to be used in asthma research. MW: 145.2 KD. Human IgG2SA
A2707 Anti-MPL / TPOR / CD110 (TA136) Anti-MPL / TPOR / CD110 (TA136) is antibody binds to MPL and recognizes a tertial structure of MPL. It can be potentially used in the treatment of congenital amegakaryocytic thrombocytopenia. MW: 143.58 KD. Human IgG1
A2964 Avizakimab (Anti-IL-21) Avizakimab (Anti-IL-21) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets interleukin-21. MW: 145.42 KD. Human IgG1
A2709 Anti-GPR44 / PTGDR2 / CD294 Anti-GPR44 / PTGDR2 / CD294 is a monoclonal antibody against a transmembrane G-protein-coupled receptor (GPR44, also known as CRTH2, PTGDR2,or CD294) with the potential to treat asthma. MW: 147.66 KD. Human IgG1
A2965 Brazikumab (Anti-IL-23) Brazikumab (Anti-IL-23) is a human IgG2 monoclonal antibody that selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for research on Crohn's disease. MW: 144.82 KD. Human IgG2SA
A2710 Anti-GOLM1 Anti-GOLM1 is a monoclonal antibody against Golgi protein-73 (GP73, Golgi Membrane Protein 1, GOLM1) with the potential to be used in research on hepatocellular carcinoma (HCC). MW: 145.62 KD. Human IgG1
A2966 Anti-IL-23 (LY2525623) Anti-IL-23 (LY2525623) is a human monoclonal antibody targeting Interleukin-23 (IL-23). It has the potential to be researched for autoimmune inflammatory diseases. MW: 144.26 KD. Human IgG1
A2711 Anti-GREM1 / Gremlin Anti-GREM1 / Gremlin is a monoclonal antibody that binds to human gremlin-1 (GREM1) with potential anti-tumor activity. MW: 144.58 KD. Human IgG4SP
A2967 Mirikizumab (Anti-IL-23) Mirikizumab (Anti-IL-23) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23. Mirikizumab can be used for research on ulcerative colitis. MW: 144.26 KD. Human IgG4SP
A2712 Erlizumab (Anti-Integrin b2 / ITGB2 / CD18) Erlizumab (anti-Integrin b2 / ITGB2 / CD18) is a humanized monoclonal antibody targeted against Integrin beta-2 and used as a therapy for hemorrhagic shock. MW: 146.66 kD. Human IgG1
A2968 Camidanlumab (Anti-IL-2Ra / CD25) Camidanlumab (HuMax-TAC) is a human IgG1 monoclonal antibody directed against CD25 (IL-2R alpha), which is overexpressed in a variety of hematological tumors. MW: 143.98 KD. Human IgG1
A2713 Anti-Nogo Receptor / NgR Anti-Nogo Receptor / NgR is a monoclonal anti-NgR antibody with the potential to promote axonal regeneration. MW: 146.18 KD. Human IgG2SA
A2969 Ocaratuzumab (Anti-CD20) Ocaratuzumab (anti-CD20) is a Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC). MW: 145.38 kD. Human IgG1
A2714 Anti-Complement Factor P / Properdin Anti-Complement Factor P / Properdin is a monoclonal anti-Properdin antibody with the potential to treat chronic complement-mediated and complement-associated disorders. MW: 145.54 KD. Human IgG1
A2970 Ociperlimab (Anti-TIGIT) Ociperlimab (anti-TIGIT) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. MW: 145.12 kD. Human IgG1
A2715 Anti-TAT226 Anti-TAT226 is a monoclonal antibody that binds to TAT226 with potential anti-tumor activity. MW: 144.66 KD. Human IgG1
A2971 Ofatumumab (Anti-CD20) Ofatumumab (Anti-CD20) is a fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. MW: 145.94 kD. Human IgG1
A2716 Anti-TMPRSS2 Anti-TMPRSS2 is a monoclonal antibody with possible antiviral activity that detects transmembrane serine protease 2 (TMPRSS2). MW: 146.06 KD. Human IgG1
A2972 Anti-IL-4Ra / CD124 (MEDI2045) Anti-IL-4Ra / CD124 (MEDI2045) is a high-affinity human and Cynomolgus cross-reactive antibody that blocks the functional interaction of IL-4 and IL-13 with their obligate receptor, IL-4Ra. MEDI 2045 has the potential to treat severe, uncontrolled asthma. MW: 143.76 KD. Human IgG1
A2717 Anti-HGFA Anti-HGFA is a monoclonal anti-HGFA antibody that detects endogenous levels of HGFA protein in biological samples. MW: 141.18 KD. Human IgG1
A2973 Anti-IL-5 (Abgenix anti-IL-5) Anti-IL-5 (Abgenix anti-IL-5) is a human monoclonal antibody against interleukin-5. MW: 145.0 KD. Human IgG4SP
A2718 Anti-KLK5 / Kallikrein 5 Anti-KLK5 / Kallikrein 5 is a monoclonal antibody kallikrein-related peptidase 5 (KLK5) with the potential to be used in research on immune-based therapies. MW: 144.76 KD. Human IgG1
A2719 Anti-Orai1 Anti-Orai1 is a human monoclonal anti-Orai1 antibody (mAb) with the potential to treat autoimmune diseases. MW: 143.86 KD. Human IgG2SA
A2975 Anti-IL-6 / IFNb2 (Chugai SK2) Anti-IL-6 / IFNb2 (Chugai SK2) is a humanized mouse monoclonal antibody that specifically binds to IL-6 and strongly inhibits IL-6 functions. MW: 145.46 KD. Human IgG1
A2720 Anti-SERPINE1 Anti-SERPINE1 is a monoclonal antibody that specifically binds to Plasminogen Activator Inhibitor Type-1 (PAI-1, SERPINE1) with the potential to be used in cardiovascular diseases. MW: 145.72 KD. Human IgG1
A2721 Anti-CXCL4 / PF4 Anti-CXCL4 / PF4 is a monoclonal antibody against anti-CXC chemokine ligand 4 (CXCL4, also called PF4). MW: 144.86 KD. Human IgG1
A2722 Anti-Albumin Anti-Albumin is a human monoclonal antibody that is specific for human serum albumin (HSA) and has the potential to be used in research on type 1 diabetes. MW: 144.24 KD. Human IgG1
A2978 Anti-IL-6 / IFNb2 (MEDI 5117) Anti-IL-6/IFNb2 (MEDI 5117) is a human monoclonal antibody against Interleukin-6 (IL-6), a pleiotropic cytokine with immune regulation, inflammation, and oncogenesis. It has the potential to treat rheumatoid arthritis (RA). MW: 145.14 KD. Human IgG1
A2723 Anti-STOP1 Anti-STOP1 is a human monoclonal antibody against stable tubule-only polypeptides (STOP), a protein responsible for microtubule cold stabilization. MW: 145.78 KD. Human IgG1
A2979 Olinvacimab (Anti-VEGFR2 / KDR / CD309) Olinvacimab (Anti-VEGFR2 / KDR / CD309) is a fully human monoclonal antibody targeting VEGFR2. It has antiangiogenic activity and can be used for the research of recurrent glioblastoma and breast cancer. MW :146.88 KD Human IgG1
A2724 Anti-TMEFF2 Anti-TMEFF2 is a human monoclonal anti-TMEFF2 antibody with potential anti-tumor activity. MW: 144.08 KD. Human IgG1
A2980 Sirukumab (Anti-IL-6 / IFNb2) Sirukumab (Anti-IL-6 / IFNb2) is a humanized monoclonal IgG1κ antibody targeting IL6 (Interleukin Related). It has the potential for active lupus nephritis research. MW :144.58 KD. Human IgG1
A2725 Anti-TIE2 / CD202b Anti-TIE2 / CD202b is a fully human monoclonal antibody that binds to human Tie2 and blocks the interaction between Tie2 or Tie2 ligands (angiopoietin). It has the potential to treat angiogenesis disorders. MW: 146.6 KD. Human IgG4SP
A2981 Ziltivekimab (Anti-IL-6 / IFNb2) Ziltivekimab (Anti-IL-6 / IFNb2) is a human monoclonal antibody targeting IL-6. It has anti-inflammatory activity and may be used in studies of chronic systemic inflammation and cardiovascular disease associated with CKD. MW :145.14 KD. Human IgG1
A2726 Anti-ANO1 / TMEM16A Anti-ANO1 / TMEM16A is a humanized monoclonal antibody that binds to human TMEM16A and modulates its activity, with potential anti-tumor activity. MW: 146.8 KD. Human IgG1-Kappa
A2982 Anti-IL-6Ra / CD126 (APX007) Anti-IL-6Ra / CD126 (APX007) is a monoclonal antibody targeting IL-6R/CD126. It can be used in the pathogenesis of multiple myeloma. MW :144.6 KD. Human IgG1
A2727 Anti-Polyubiquitin Anti-Polyubiquitin is a monoclonal anti-Polyubiquitin antibody used for isolating polyubiquitin chain-tagged proteins. MW: 144.98 KD. Human IgG1
A2983 Levilimab (Anti-IL-6Ra / CD126) Levilimab (Anti-IL-6Ra / CD126) is a fully human monoclonal antibody targeting interleukin-6 receptor (IL-6R). It is an inflammation-alleviating antibody and can be used for the research of rheumatoid arthritis and covid-19 treatment. MW :145.62 KD. Human IgG1
A2728 Anti-SCN9a / Nav1.7 Anti-SCN9a / Nav1.7 is a fully human antibody that binds to human Nav1.7 (hNav1.7, SCN9a) with the potential to treat acute or chronic pain conditions or inflammatory conditions. MW: 145.72 KD. Human IgG1
A2984 Sapelizumab (Anti-IL-6Ra / CD126) Sapelizumab (Anti-IL-6Ra / CD126) is a human monoclonal antibody targeting IL-6. It is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. MW :144.26 KD. Human IgG2SA
A2985 Olokizumab (Anti-IL-6 / IFNb2) Olokizumab (Anti-IL-6 / IFNb2) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). It can be used in research of rheumatoid arthritis (RA). MW :145.4 KD. Human IgG4SP
A2730 Anti-Histone H3 Anti-Histone H3 is a monoclonal anti-Histone H3 antibody antibody used for detection of Histone H3 (histone 3-H3). MW: 150 KD. Human IgG1
A2986 Omburtamab (Anti-B7-H3 / CD276) Omburtamab (Anti-B7-H3 / CD276) is a monoclonal antibody targeting CD276 (also known as B7-H3). It can bind tumor tissues and be used in various cancers research like non-small cell lung cancer (NSCLC). MW :145.04 KD. Human IgG1
A2731 Anti-RG1 (19G9) Anti-RG1 (19G9) is a fully human antibody target against the mindin/RG-1 protein, which exhibits high abundance in LNCaP tumor xenografts. MW: 144.14 kD. Human IgG1
A2987 Ongericimab (Anti-PCSK9) Ongericimab (Anti-PCSK9) is a humanized monoclonal antibody targeting PCSK9. It has lipid-lowering efficacy and can be used in research of hypercholesteremia and hyperlipidemia. MW :143.04 KD. Human IgG4SP
A2732 Anti-ANGPTL8 Anti-ANGPTL8 is a monoclonal antibody againts Angiopoietin-like protein (ANGPTL8) with potential to treat hypertriglyceridemia. MW: 145.16 KD. Human IgG2SA
A2988 Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1)) Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1)) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). It can be used for the research of multiple sclerosis. MW: 144.56 KD. Human IgG4SP
A2733 Anti-CXC-ELR Anti-CXC-ELR is a monoclonal antibody that binds to an ELR+ CXC chemokine and inhibits its biological activity. MW: 146.56 KD. Human IgG4SP
A2734 Anti-HTRA1 (FHTR2163) Anti-HTRA1 (FHTR2163) is an antigen-binding fragment (Fab) directed against high-temperature requirement protein A1 (HtrA1) which preserves retinal integrity and slow disease progression in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). MW: 144.6 kD. Human IgG1
A2990 Intetumumab (Anti-Integrin aV / ITGAV / CD51) Intetumumab (Anti-Integrin aV / ITGAV / CD51) is a potent monoclonal antibody targeting αV-integrins. It can be used in research of uterine serous papillary carcinoma (USPC) treatment. MW :145.58 KD. Human IgG1
A2991 Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3)) Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3)) is an IgG1 monoclonal antibody targeting αvβ3 integrin. It inhibits angiogenesis and melanoma tumor growth and can be used to research anticancer. MW :144.18 KD. Human IgG1
A2736 Anti-DLK1 (LIV-1205) Anti-DLK1 (LIV-1205) is a humanized monoclonal antibody targeting cell surface antigen DLK-1 (Deltalike 1 homolog). MW: 147.34 kD. Human IgG1
A2992 Oportuzumab (Anti-EpCAM / TROP1 / CD326) Oportuzumab (Anti-EpCAM / TROP1 / CD326) is a humanized monoclonal antibody targeting EpCAM. It exhibits potential in treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. MW :145.4 KD. Human IgG1
A2737 Anti-Matriptase Anti-Matriptase is a monoclonal matriptase-specific antibody. MW: 144.28 KD. Human IgG1
A2993 Encelimab (Anti-LAG3 / CD223) Encelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody targeting the inhibitory receptor lymphocyte activation gene 3 protein (LAG3). It has potential immune checkpoint inhibitory and antineoplastic, antitumor activity. MW :144.58 KD. Human IgG4SP
A2994 Favezelimab (Anti-LAG3 / CD223) Favezelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody that targets LAG-3. It has the potential for colorectal cancer (CRC) research. MW :145.98 KD. Human IgG4SP
A2739 Anti-158P1D7 Anti-158P1D7 is a monoclonal anti-158P1D7 antibody used in the production of antibody drug conjugates (adc) that bind to 158P1D7 proteins. MW: 146.0 KD. Human IgG2SA
A2995 Fianlimab (Anti-LAG3 / CD223) Fianlimab (Anti-LAG3 / CD223) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells. It has anti-tumour activity and can be used in treatment of advanced melanoma. MW :145.72 KD. Human IgG4SP
A2740 Anti-Dysadherin Anti-Dysadherin is a monoclonal antibody against dysadherin with anti-metastasis activity. MW: 147.56 KD. Human IgG1
A2996 Ieramilimab (Anti-LAG3 / CD223) Ieramilimab (Anti-LAG3 / CD223) is a humanized IgG4 monoclonal antibody that targets LAG-3. It has antitumor activity and can be used in treatment of advanced malignancies MW :146.78 KD. Human IgG4SP
A2741 Anti-TMEFF1 / Tomoregulin-1 Anti-TMEFF1 / Tomoregulin-1 is a monoclonal antibody against TMEFF1 (a transmembrane protein with EGF-like and two Follistatin-like domains, Tomoregulin 1), a type I transmembrane glycoprotein. MW: 146.08 KD. Human IgG1
A2997 Miptenalimab (Anti-LAG3 / CD223) Miptenalimab (Anti-LAG3 / CD223) is an anti-human LAG-3 antibody. It leads to an increased immune cell responses. MW :146.12 KD. Human IgG4SP
A2742 Anti-c-RET Anti-c-RET is a monoclonal antibody against the receptor tyrosine kinase Ret (c-Ret) expressed in cells of neuroblastoma and substantia nigra, a responsive locus of Parkinson's disease. MW: 146.74 KD. Human IgG1
A2998 Opucolimab (Anti-B7-H1 / PD-L1 / CD274) Opucolimab (Anti-B7-H1 / PD-L1 / CD274) is a recombinant human monoclonal antibody targeting PD-L1. It can be used for the research of advanced solid tumors. MW :144.68 KD. Human IgG1
A2743 Cantuzumab (Anti-MUC1) Cantuzumab (Anti-MUC1) is a humanized monoclonal antibody that targets aganits cell surface-associated mucin 1 (MUC1) expressed in most pancreatic cancers.MW: 147.02 kD. Human IgG1
A2744 Abituzumab (Anti-Integrin aV / ITGAV / CD51) Abituzumab (Anti-Integrin aV / ITGAV / CD51) is a humanized monoclonal antibody directed against the human alpha v integrin subunit with potential antiangiogenic and antineoplastic activities.MW: 144.78 kD. Human IgG2SA
A3000 Orilanolimab (Anti-FcRn (FCGRT & B2M)) Orilanolimab (Anti-FcRn (FCGRT & B2M)) is a humanized monoclonal antibody targeting FcRn. It disrupts the interaction of FcRn and IgG for the treatment autoimmune diseases. MW :144.28 KD. Human IgG4SP
A2745 Anti-Integrin a11 / ITAG11 Anti-Integrin a11 / ITAG11 is a monoclonal antibody against Integrin alpha 11 (ITGA11), a transmembrane glycoprotein expressed in adult cardiac and uterine smooth muscle and developing myocytes. MW: 145.7 KD. Human IgG2SA
A3001 Anti-AXL / UFO (ORY012) Anti-AXL / UFO (ORY012) is a polyclonal antibody that targets receptor tyrosine kinase AXL (UFO). It can be used in research of glioblastoma multiforme (GBM) and pancreatic cancers. MW :146.28 KD. Human IgG1
A2746 Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) is a humanized IgG1-based bispecific antibody that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. MW: 145.24 kD. Human IgG1
A3002 Anti-Mesothelin (BMS-986148) Anti-Mesothelin (BMS-986148) is a fully human IgG1 monoclonal antibody targeting mesothelin. It is used to synthesize antibody-drug conjugate (ADC). It has potential multimodal therapeutic strategies in patients with advanced solid tumors. MW :150 KD. Human IgG1
A2747 Cusatuzumab (Anti-TNFSF7 / CD27L / CD70) Cusatuzumab (Anti-TNFSF7 / CD27L / CD70) is a defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML). MW: 144.36 kD. Human IgG1
A2748 Anti-SCFR / c-Kit / CD117 (CDX-0158) Anti-SCFR / c-Kit / CD117 (CDX-0158) is a humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. CDX‐0159 inhibits SCF‐dependent KIT and mast cell activation. MW: 145.1 kD. Human IgG1
A3004 Otelixizumab (Anti-CD3) Otelixizumab (Anti-CD3) is a human monoclonal antibody targeting CD3. It can be used for the research of type 1 diabetes. MW :145.14 KD. Human IgG1
A2749 Anti-DSG3 Anti-DSG3 is an anti-desmoglein 3 (Dsg3) monoclonal antibody that depletes desmosomes of Dsg3 and has the potential to be used in research on Pemphigus vulgaris (PV). MW: 146.54 KD. Human IgG1
A3005 Anti-MUC1 (AR20.5) Anti-MUC1 (AR20.5) is a murine monoclonal antibody targeting tumor-associated antigen MUC1. It has anti-tumor activity and can be used in research of potential cancer vaccine. MW :140.36 KD. Human IgG1
A2750 Anti-FcgR3a / CD16a (AFM13) Anti-FcgR3a / CD16a (AFM13) is a tetravalent bispecific antibody directed against human CD30 and the human low affinity IgG Fc region receptor (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. MW: 143.56 kD. Human IgG2SA
A3006 Anti-INHBB / Activin B Anti-INHBB / Activin B is a monoclonal antibody targeting the betaB subunit of Activin B. It has potent uses in treatment of fatigue syndrome/myalgic encephalomyelitis (CFS/ME). MW:146.02 KD. Human IgG1
A3007 Anti-NGF / bNGF (AS2886401-00) Anti-NGF / bNGF (AS2886401-00) is a monoclonal antibody targeting nerve growth factor (NGF). It holds tremendous potential for the management of osteoarthritis (OA). MW :139.0 KD. Human IgG2SA
A2752 Anti-MUSK Anti-MUSK is a monoclonal IgG antibody against muscle-specific kinase (MuSK) with the potential to treat Myasthenia gravis. MW: 145.24 KD. Human IgG1
A3008 Fasinumab (Anti-NGF / bNGF) Fasinumab (Anti-NGF / bNGF) is a human IgG1k monoclonal antibody targeting nerve growth factor (NGF). It can be used in acute sciatica and knee osteoarthritis (OA) studies. MW :144.9 KD. Human IgG1
A2753 Anti-MICA (CLN-619) Anti-MICA (CLN-619) is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the natural-killer group 2, member D receptor protein (NKG2D or KLRK1) ligands MHC class I polypeptide-related sequence A (MICA) and B (MICB), with potential immunostimulating and antineoplastic activities. MW: 146.06 kD. Human IgG1
A3009 Anti-NGF / bNGF (MEDI-578) Anti-NGF / bNGF (MEDI-578) is a monoclonal antibody targeting nerve growth factor (NGF). It holds tremendous potential for the management of osteoarthritis (OA). MW :145.42 KD. Human IgG4SP
A2754 Anti-TREM1 / CD354 (PY159) Anti-TREM1 / CD354 (PY159) is a humanized agonistic monoclonal antibody targeting triggering receptor expressed on myeloid cells 1 (TREM1), with potential immunomodulating and antineoplastic activities. MW: 143.66 kD. Human IgG1
A3010 Uliledlimab (Anti-NT5E / CD73) Uliledlimab (Anti-NT5E / CD73) is a humanized monoclonal antibody targeting CD73. It can be used in research of cancer and treatment naive NSCLC. MW :145.06 KD. Human IgG1
A2755 Anti-CDH11 / Cadherin-11 (RG6125) Anti-CDH11 / Cadherin-11 (RG6125) is a humanized monoclonal antibody that binds cadherin 11 an adhesion molecule expressed by FLS that is involved in synovial intimal lining aggregation. It has the potential to research FLS-targeted rheumatoid arthritis. MW: 146.4 kD. Human IgG2SA
A2756 Anti-SCN11a / Nav1.9 Anti-SCN11a / Nav1.9 is a monoclonal anti-Nav1.9 (SCN11A) antibody used in antigen-specific immunodetection in biological samples. MW: 143.94 KD. Human IgG1
A3012 Vixarelimab (Anti-OSMR) Vixarelimab (Anti-OSMR) is a human monoclonal antibody that targets oncostatin M (OSM). It can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash. MW :145.34 KD. Human IgG4SP
A2757 Anti-TLR7 Anti-TLR7 is a monoclonal antibody against Toll-like receptor 7 (TLR7) with the potential to treat autoimmune disease. MW: 145.04 KD. Human IgG1
A3013 Plonmarlimab (Anti-CSF2 / GM-CSF) Plonmarlimab (Anti-CSF2 / GM-CSF) is a monoclonal antibody targeting GM-CSF. It can be used for research of rheumatoid arthritis and COVID-19. MW :145.96 KD. Human IgG1
A2758 Drozitumab (Anti-TNFRSF10B / TRAILR2 / CD262) Drozitumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal antibody targeted against the death receptor DR5 (TRAILR2, CD262, TNFRSF10B) with potent anti-tumor activity against rhabdomyosarcoma (RMS) xenografts. MW: 150 kD. Human IgG1
A3014 Ponezumab (Anti-Amyloid Beta) Ponezumab (Anti-Amyloid Beta) is a humanised IgG2 monoclonal antibody amyloid. It can be used in study of Alzheimer's disease. MW :145.66 KD. Human IgG2SA
A2759 Selicrelumab (Anti-TNFRSF5 / CD40) Selicrelumab (anti-TNFRSF5 / CD40) is a human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. It induces changes in the tumor microenvironment and can be used for the research of pancreatic cancer and neoadjuvant tudies. MW: 146.2 kD. Human IgG2SA
A2760 Lintuzumab (Anti-Siglec-3 / CD33) Lintuzumab (HuM195) is a humanized monoclonal antibody that targets CD33, a 67-kDa cell surface glycoprotein expressed on most myeloid leukemia cells. MW: 145. 24 kD. Human IgG1
A3016 Pozelimab (Anti-Complement C5) Pozelimab (Anti-Complement C5) is a fully human IgG4 monoclonal antibody targeting C5. It can be used for the research of complement-mediated diseases. MW :144.78 KD. Human IgG4SP
A2761 Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) is a fully human monoclonal immunoglobulin G2 antibody that targets the alpha4beta7 integrin and prevents interaction with MADCAM-1. It has the potential to be used in research on inflammatory bowel disease (IBD). MW: 143.8 kD. Human IgG2
A3017 Anti-PCLA Anti-PCLA is a fully human IgG4 monoclonal antibody targeting prostate cancer lipid-like antigen (PCLA) It can be used in treatment of prostate cancer. MW :145.52 KD. Human IgG1
A2762 Amlitelimab (Anti-TNFSF4 / OX40L / CD252) Amlitelimab (Anti-TNFSF4 / OX40L / CD252) is a nondepleting IgG4 human anti-OX40L monoclonal antibody with the potential to treat atopic dermatitis. MW: 145.94 kD. Human IgG4SP
A3018 Prolgolimab (Anti-PDCD1 / PD-1 / CD279) Prolgolimab (Anti-PDCD1 / PD-1 / CD279) is a human IgG1 monoclonal antibody targeting PD-1. It can be used for the research of advanced melanoma. MW :145.14 KD. Human IgG1
A3019 Anti-MRC2 / CD280 Anti-MRC2 / CD280 is a monoclonal antibody targeting ENDO180. It can be used as therapeutic strategy of sarcoma subtypes, primary tumor and in metastatic disease. MW :142.92 KD. Human IgG1
A2764 Crenezumab (Anti-Amyloid Beta) Crenezumab (Anti-Amyloid Beta) is a fully humanized  immunoglobulin (Ig) G4 monoclonal antibody that targets amyloid beta (Abeta) with potential for use in Alzheimer's disease research. MW: 143.58 kD. Human IgG4SP
A3020 Quavonlimab (Anti-CTLA-4 / CD152) Quavonlimab (Anti-CTLA-4 / CD152) is a monoclonal antibody targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). It exhibits efficacy in first-line treatment of advanced non-small-cell lung cancer. MW :144.24 KD. Human IgG1
A2766 Gantenerumab (Anti-Amyloid Beta) Gantenerumab (Anti-Amyloid Beta) is a fully human IgG1 monoclonal antibody against beta-amyloid (Abeta40/42) used in the treatment of Alzheimer's disease. MW: 146.28 kD. Human IgG1
A3022 Ralpancizumab (Anti-PCSK9) Ralpancizumab (Anti-PCSK9) is a monoclonal antibody targeting selective proprotein convertase subtilisin kexin 9 (PCSK9). It has the potential in hemorrhagic stroke, hypercholesterolemic, dyslipidemia treatment. MW 145.28 KD. Human IgG2SA
A2767 GSK 933776 (Anti-Amyloid Beta) GSK 933776 (Anti-Amyloid Beta) is a humanized monoclonal antibody against beta-amyloid used in the treatment of Alzheimer's disease. MW: 145.34 kD. Human IgG1
A3023 Recaticimab (Anti-PCSK9) Recaticimab (Anti-PCSK9) is a humanized monoclonal antibody that targets PCSK9. It has potential application in hypercholesterolemia. MW :148.28 KD Human IgG1
A2768 Alomfilimab (Anti-ICOS / CD278) Alomfilimab (Anti-ICOS / CD278) is a human immunoglobulin G1 (IgG1) kappa monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. MW: 146.5 kD. Human IgG1
A3024 Anti-PCSK9 (RG7652) Anti-PCSK9 (RG7652) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). It exhibits potential efficacy in coronary heart disease (CHD). MW :144.84 KD. Human IgG1
A2770 Anti-ANGPT2 (MEDI3617) Anti-ANGPT2 (MEDI3617) is a human IgG1 kappa monoclonal antibody directed against the angiogenic cytokines angiopoietin-2 (Angpt2). MEDI3617 in combination with tremelimumab is used to treat advanced melanoma. MW: 145.82 kD. Human IgG2SA
A3026 Anti-ASIC1 Anti-ASIC1 is a mouse monoclonal antibody targeting acid-sensing ion channel-1 (ASIC1). It exhibits potential application in pain,neurodegenerative diseases, and psychiatric diseases. MW :144.04 KD. Human IgG1
A2771 Zansecimab (Anti-ANGPT2) Zansecimab (Anti-ANGPT2) is a humanized and engineered immunoglobulin G4 (IgG4) isotype monoclonal antibody against the proangiogenic cytokine angiopoietin 2 (Ang2) with potential anti-angiogenic activity. MW: 145.74 kD. Human IgG4SP
A3027 Balstilimab (Anti-PDCD1 / PD-1 / CD279) Balstilimab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting the programmed cell death 1 (PD-1, PCD-1; PDCD1). It exhibits potential treatment of cervical cancer. MW :137.3 KD. Human IgG4SP
A2772 Anti-ANGPTL4 Anti-ANGPTL4 is a monoclonal antibody against Angiopoietin-like 4 (ANGPTL4) with potential anti-tumor and anti-angiogenic activity. MW: 146.12 KD. Human IgG1
A3028 Budigalimab (Anti-PDCD1 / PD-1 / CD279) Budigalimab (Anti-PDCD1 / PD-1 / CD279) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. It can be used in the treatment of advanced solid tumors. MW :145.84 KD. Human IgG1
A2773 Anti-MSPR / RON / CD136 Anti-MSPR / RON / CD136 is a monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), and can be used in cancer research. MW: 139.86 KD. Human IgG1
A3029 Cetrelimab (Anti-PDCD1 / PD-1 / CD279) Cetrelimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody targeting programmed cell death 1 (PD-1). It inhibits tumor growth in vivo. MW :145.04 KD. Human IgG4SP
A2774 Mipasetamab (Anti-AXL / UFO) Mipasetamab (Anti-AXL / UFO) is a human monoclonal IgG1κ antibody targeting AXL, a tyrosine kinase receptor, and an TAM receptor, which involves the synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). MW: 145.78 kD. Human IgG1
A2775 Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, cluster of differentiation 274, CD274) with promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). MW: 145.8 kD. Human IgG4SP
A3031 Ezabenlimab (Anti-PDCD1 / PD-1 / CD279) Ezabenlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. It can be used in the treatment of advanced solid tumors. MW :145.48 KD. Human IgG4SP
A2776 Batoclimab (Anti-FcRn (FCGRT & B2M)) Batoclimab (anti-FcRn (FCGRT & B2M)) is a human monoclonal antibody directed against the neonatal crystallizable fragment receptor (FcRn) with potential immunomodulating activity. It has the potential to be used in research on autoimmune diseases mediated by pathogenic IgG antibodies. MW: 143.76 kD. Human IgG1
A2778 Garivulimab (Anti-B7-H1 / PD-L1 / CD274) Garivulimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.3 KD. Human IgG1
A3034 Penpulimab (Anti-PDCD1 / PD-1 / CD279) Penpulimab (Anti-PDCD1 / PD-1 / CD279) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. It exhibits antitumor activities. MW 145.14 KD. Human IgG1
A2779 Befovacimab (Anti-TFPI) Befovacimab (anti-TFPI) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitors (TFPI) with the potential to be used in  haemophilia A/B research. MW: 143.24 kD. Human IgG2SA
A3035 Pidilizumab (Anti-PDCD1 / PD-1 / CD279) Pidilizumab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody targeting human PD-1 (programmed cell death 1; PDCD1). It has immunomodulating and antitumor activities and can be used in treatment of metastatic melanoma. MW :144.48 KD. Human IgG1
A2780 Manelimab (Anti-B7-H1 / PD-L1 / CD274) Manelimab (Anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 143.68 kD. Human IgG1
A3036 Pimivalimab (Anti-PDCD1 / PD-1 / CD279) Pimivalimab (Anti-PDCD1 / PD-1 / CD279) is human monoclonal antibody targeting human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279). It can be used for the research of solid tumor. MW :144.5 KD. Human IgG4SP
A2781 Pacmilimab (Anti-B7-H1 / PD-L1 / CD274) Pacmilimab (anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 152.6 kD. Human IgG4SP
A3037 Retifanlimab (Anti-PDCD1 / PD-1 / CD279) Retifanlimab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting programmed cell death protein 1 (anti-PD-1). It can be used for the research of gastroesophageal adenocarcinoma (GEA). MW :145.64 KD. Human IgG4SP
A2782 Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1-kappa, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), monoclonal antibody. MW: 144.6 kD. Human IgG1
A3038 Sasanlimab (Anti-PDCD1 / PD-1 / CD279) Sasanlimab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting programmed cell death protein 1 (anti-PD-1). It has potential antineoplastic activities and can be used in the treatment of advanced or metastatic non-small-cell lung cancer and urothelial carcinoma. MW :146.46 KD. Human IgG4SP
A2783 Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small-cell lung cancer research. MW: 143.36 kD. Human IgG1
A3039 Tislelizumab (Anti-PDCD1 / PD-1 / CD279) Tislelizumab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting programmed cell death protein 1 (anti-PD-1). It can be used for the research of advanced squamous non-small-cell lung cancer. MW :144.46 KD Human IgG4SP
A3041 Zimberelimab (Anti-PDCD1 / PD-1 / CD279) Zimberelimab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting programmed cell death protein 1 (anti-PD-1). It shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma. MW :144.72 KD. Human IgG4SP
A2786 Anti-BACE1 (Genentech anti-BACE1) Anti-BACE1 (Genentech anti-BACE1) is a monoclonal anti-BACE1 antibody (mAb) that reduces endogenous BACE1 activity and amyloid-β (Aβ) production. It has the potential to treat Alzheimer's disease. MW: 144.22 KD. Human IgG1
A3042 Revdofilimab (Anti-TNFRSF4 / OX40 / CD134) Revdofilimab (Anti-TNFRSF4 / OX40 / CD134) is a human IgG1 agonist monoclonal antibody targeting OX40. It has antitumor activity and can be used in research of advanced solid tumors. MW :145.54 KD. Human IgG1
A2787 Blosozumab (Anti-SOST / Sclerostin) Blosozumab (anti-SOST/ Sclerostin) is a humanized monoclonal antibody against sclerostin. Blosozumab stimulates bone formation, reduces bone resorption, and has the potential to be used in the research of osteoporosis. MW: 144.88 kD. Human IgG4SP
A3043 Anti-PDGFRB / CD140b (IMC-2C5) Anti-PDGFRB / CD140b (IMC-2C5) is a fully human antagonistic antibody targeting PDGFRβ It enhances antitumor activity and antiangiogenic agents in the treatment of a broad range of human cancers. MW :145.06 KD. Human IgG1
A2788 Bococizumab (Anti-PCSK9) Bococizumab (Anti-PCSK9) is a humanized monoclonal IgG2Δa antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) used for the treatment of hyperlipidemia. MW: 145.06 kD. Human IgG2SA
A3044 Robatumumab (Anti-IGF1R / CD221) Robatumumab (Anti-IGF1R / CD221) is an antibody targeting human IGF-1R (insulin-like growth factor receptor-1). It shows anti-tumor activity and anti-proliferative activity to cancer cells and can be used in osteosarcoma and Ewing sarcoma research. MW :144.6 KD Human IgG1
A2789 Anti-PCSK9 (Boehringer anti-PCSK9) Anti-PCSK9 (Boehringer anti-PCSK9) is a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) that prevents PCSK9-mediated degradation of the LDLR.MW: 146.42 kD. Human IgG1
A2790 Eptinezumab (Anti-CALCA / CGRP) Eptinezumab (Anti-CALCA / CGRP) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the receptor. It is used in the preventive treatment of episodic migraine. MW: 143.36 kD. Human IgG1
A3046 Anti-CYR61 / CCN1 Anti-CYR61 / CCN1 is a monoclonal antibody targeting cysteine-rich protein 61(CCN1/Cyr61) . It can be used in breast cancer treatment. MW :144.42 KD. Human IgG1
A2791 Fremanezumab (Anti-CALCA / CGRP) Fremanezumab (Anti-CALCA / CGRP) is a humanized IgG2a monoclonal antibody that selectively and potently targets calcitonin gene-related peptide (CGRP). Fremanezumab has the potential for chronic migraine research.. MW: 145.5 kD. Human IgG2SA
A3047 Anti-PRLR / Prolactin Receptor (BAY 1158061) Anti-PRLR / Prolactin Receptor (BAY 1158061) is a potent monoclonal antibody, targeting prolactin (PRL) receptor. It is considered a good candidate for further development in endometriosis or other PRL-mediated disease conditions. MW :143.8 KD Human IgG1
A2792 Anti-ABCB5 Anti-ABCB5 is a monoclonal antibody (mAb) against ABCB5 (ATP-binding cassette transporter, sub-family B (MDR/TAP), member 5) with the potential to be used in research on melanoma. MW: 147.74 KD. Human IgG1
A2793 Anti-CD151 Anti-CD151 is an anti-CD151 monoclonal antibody (mAb) with potential anti-metastatic and anti-tumor activity activity. MW: 146.76 KD. Human IgG1
A3049 Anti-RAMP3 Anti-RAMP3 is a polyclonal antibody targeting RAMP2. It is useful in the treatment of cancer. MW :147.04 KD. Human IgG1
A2794 Anti-EMMPRIN / CD147 Anti-EMMPRIN / CD147 is a monoclonal antibody against extracellular matrix metalloproteinase inducer (EMMPRIN; CD147) with potential anti-proliferative activity. MW: 145.42 KD. Human IgG1
A3050 Anti-RHD / CD240d (LFB Anti-RhD) Anti-RHD / CD240d (LFB Anti-RhD) is a polyclonal IgG antibody specificly targeting RhD (rhesus D). It is used in the treatment of fetal hemolytic disease. MW :147.46 KD. Human IgG1
A2795 Denintuzumab (Anti-CD19) Denintuzumab (anti-CD19) is a recombinant humanized anti-CD19 monoclonal antibody that can be used in the research of acute lymphoblastic leukemia. Denintuzumab can be used to synthesize ADC antibody Denintuzumab Mafodotin (SGN-CD19A). MW: 145.0 kD. Human IgG1
A3051 Atinumab (Anti-RTN4 / NOGO) Atinumab (Anti-RTN4 / NOGO) is a monoclonal antibody targeting reticulon-4. It has immunomodulating activity and can be used for the research of spinal cord injury (SCI). MW :137.82 KD. Human IgG4SP
A3052 Anti-S100A4 (LK-1) Anti-S100A4 (LK-1) is a monoclonal antibody targeting the small Ca-binding protein, S100A4. It can be used in development of an efficient anti-metastatic therapy in various cancers. MW :145.04 KD. Human IgG1
A2797 Anti-IL-25 Anti-IL-25 is a humanised monoclonal antibody against Interleukin-25 (IL-25) with the potential to treat airway hyperresponsiveness (AHR). MW: 146.02 KD. Human IgG1
A3053 Anti-BST2 / CD317 Anti-BST2 / CD317 monoclonal antibody that targets Bone marrow stromal antigen 2. It can be used in cancer research. MW :145.52. KD. Human IgG1
A2798 Certolizumab (Anti-TNFSF2 / TNFa) Certolizumab (anti-TNFSF2 / TNFa) is a Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) with anti-inflammatory activity. MW: 144.92 kD. Human IgG1
A3054 Anti-Siglec-15 / CD33L3 (AB-25E9) Anti-Siglec-15 / CD33L3 (AB-25E9) is a humanized monoclonal antibody targeting sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15). It may have potential as an anti-resorptive therapy for osteoporosis. MW :150 KD. Human IgG1
A2800 Anti-Amyloid Beta (CNTO 2125) Anti-Amyloid Beta (CNTO 2125) is a human monoclonal antibody against amyloid beta has the potential to be used in Alzheimer's disease (AD) research. MW : 143.86 KD. Human IgG1
A3056 Epratuzumab (Anti-Siglec-2 / CD22) Epratuzumab (Anti-Siglec-2 / CD22) is a IgG1 monoclonal antibody targeting CD22. It has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases. MW: 155.4 KD. Human IgG4SP
A2801 Anti-IL-13 (CNTO 607) Anti-IL-13 (CNTO 607) is a recombinant human antibody against interleukin 13 (IL-13). MW : 144.14 KD. Human IgG1
A3057 Anti-Siglec-2 / CD22 (NCI m971) Anti-Siglec-2 / CD22 (NCI m971) is a humanized monoclonal antibody targeting CD22, a Siglec family lectin present on B cells. It is used in treatment of acute lymphoblastic leukemia (ALL). MW :146.64 KD. Human IgG1
A2802 Cobolimab (Anti-TIM-3 / HAVCR2 / CD366) Cobolimab (Anti-TIM-3 / HAVCR2 / CD366) is a monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 142.84 KD. Human IgG1
A3058 Anti-Siglec-2 / CD22 (NCI m972) Anti-Siglec-2 / CD22 (NCI m972) is a humanized monoclonal antibody targeting CD22, a Siglec family lectin present on B cells. It is a promising novel therapeutics for B-cell acute lymphoblastic leukemia (BCP-ALL). MW :144.3 KD. Human IgG1
A2803 Cofetuzumab (Anti-PTK7 / CCK4) Cofetuzumab (Anti-PTK7 / CCK4) is humanized IgG1 monoclonal antibody against protein tyrosine kinase 7 (PTK7) with potential antitumor activity. MW : 146.7 KD. Human IgG1
A3059 Pinatuzumab (Anti-Siglec-2 / CD22) Pinatuzumab (Anti-Siglec-2 / CD22)a humanized IgG1 monoclonal antibody targeting CD22. It has potential antineoplastic activity and can be used in research of Non-Hodgkin Lymphoma. MW : 146.64 KD. Human IgG1
A2804 Coltuximab (Anti-CD19) Coltuximab (Anti-CD19) is humanized IgG1 monoclonal antibody against CD19 with potential antineoplastic activity. MW : 144.7 KD. Human IgG1
A2805 Ripertamab (Anti-CD20) Ripertamab (Anti-CD20) is a chimeric monoclonal antibody directed against human CD20 with potential antineoplastic activity. MW : 144.56 KD. Human IgG1
A3061 Azintuxizumab (Anti-SLAMF7 / CS1) Azintuxizumab (Anti-SLAMF7 / CS1/ CD319/ CRACC) is a monoclonal IgG4 bispecific antibody targeting B-cell maturation antigen (BCMA). It has the potential for the research of relapsed/refractory multiple myeloma (RRMM). MW :140.12 KD. Human IgG1
A2806 Anti-CD20 (TRU-015) Anti-CD20 (TRU-015) is a small proprietary antibody-based single-chain polypeptide that binds to CD20 and effectively depleted B cells. It exhibits anti-tumor activity in human tumor xenograft models. MW : 145.4 KD. Human IgG1
A3062 Anti-SLAMF7 / CS1 (PDL241) Anti-SLAMF7 / CS1 (PDL241) is a novel humanized monoclonal antibody, targeting CD319. It is a promising therapeutic target for rheumatoid arthritis. MW :144.92 KD. Human IgG1
A2807 Ublituximab (Anti-CD20) Ublituximab (Anti-CD20) is a chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity.  MW : 145.22 KD. Human IgG1
A3063 Anti-SLC2A8 (VB1-050) Anti-SLC2A8 (VB1-050) is amonoclonal antibody ADCC, targeting SLC2A8. It is used in the various cancer treatment including breast, liver, prostate and colon cancers. MW :145.08 KD. Human IgG1
A2808 Veltuzumab (Anti-CD20) Veltuzumab (Anti-CD20) is a humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. MW : 145.22 KD. Human IgG1
A3064 Solanezumab (Anti-Amyloid Beta) Solanezumab (Anti-Amyloid Beta) is a humanized monoclonal IgG1 antibody targeting the mid-domain of the amyloid-β (Aβ) peptide. It has the potential for the research of Alzheimer’s disease. MW :144.34 KD. Human IgG1
A2809 Zuberitamab (Anti-CD20) Zuberitamab (Anti-CD20) is a human monoclonal antibody that targets CD20, with the potential to be used in research on diffuse large B-cell lymphoma. MW : 145.48 KD. Human IgG1
A3065 Tadocizumab (Anti-Integrin a2b3 (ITGA2 & ITGB3)) Tadocizumab (Anti-Integrin a2b3 (ITGA2 & ITGB3)) is a humanized monoclonal antibody tageting integrin αIIbβ3. It has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research. MW :145.3 KD. Human IgG1
A2810 Coprelotamab (Anti-ERBB2 / HER2 / CD340) Coprelotamab (Anti-ERBB2 / HER2 / CD340) is humanized monoclonal antibody targated against HER2 with the potential to treat breast cancer. MW : 145.36 KD. Human IgG1
A3066 Bepranemab (Anti-Tau) Bepranemab (Anti-Tau) is a humanized, full-length IgG4 monoclonal antibody that targets to a central tau epitope (amino acids 235-250).It can be used for Alzheimer’s disease (AD) research. MW :145.92 KD. Human IgG4SP
A2811 Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.64 KD. Human IgG1
A3067 Tafolecimab (Anti-PCSK9) Tafolecimab (Anti-PCSK9) is a human lgG2 monoclonal antibody that specifically targets PCSK-9. It may be used in studies of hypercholesterolaemia. MW :145.34 KD. Human IgG2SA
A2812 Crovalimab (Anti-Complement C5) Crovalimab (Anti-Complement C5) is a humanized recycling monoclonal antibody directed against the complement pathway protein C5, with potential complement pathway inhibitory and immunomodulating activities. MW : 145.28 KD. Human IgG1
A3068 Anti-TCR (NKTT320) Anti-TCR (NKTT320) is a novel humanized monoclonal antibody specificly targeting for the invariant TCR. It is used use in cell-based cancer immunotherapy. MW :146.14 KD. Human IgG4SP
A2370 Elezanumab (Anti-RGMA) Elezanumab (Anti-RGMA) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway with IC50 of 97 pM. MW: 146.44 kD. Human IgG1
A2371 Anti-PVRIG Anti-PVRIG is a humanized, hybridoma monoclonal antibody against the poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), with potential immune checkpoint inhibitory and antineoplastic activities.MW: 145.5 kD. Human IgG4SP
A2373 Neihulizumab (Anti-PSGL1 / CD162) Neihulizumab (Anti-PSGL1 / CD162) is a humanized, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1, SELPLG, CD162) with potential immunosuppressive activity. It can halt the progression of T-cell-mediated autoimmune diseases and acute graft-versus-host disease (GvHD). MW: 150 kD. Human IgG4SP
A2374 Crizanlizumab (Anti-P-Selectin / CD62p) Crizanlizumab (Anti-P-Selectin / CD62p) is a humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. MW: 144.24 kD. Human IgG2SA
A2375 Rolinsatamab (Anti-PRLR / Prolactin Receptor) Rolinsatamab (Anti-PRLR / Prolactin Receptor) is a fully humanized bispecific monoclonal antibody that targets IL-4 and IL-13. MW: 145.5 kD. Human IgG1
A2379 Olaratumab (Anti-PDGFRA / CD140a) Olaratumab (IMC-3G3; LY3012207) is a fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. MW: 145.5 kD. Human IgG1
A2384 Anti-PAR2 Anti-PAR2 is a antibody against Protease-Activated Receptor 2 (PAR2). MW: 145.5 kD. Human IgG1
A2385 Zelminemab (Anti-PAC1) Zelminemab (AMG-301) is a human monoclonal antibody that inhibits the PACAP type I (PAC1) receptor. MW: 145.5 kD. Human IgG1
A2386 Orticumab (Anti-oxLDL) Orticumab (MLDL1278A) is an antibody targeting oxidized or malondialdehyde-modified lipoprotein (LDL) that specifically inhibits oxidised low-density lipoproteins (oxLDL). Orticumab is involved in the modulation of autoimmune responses against oxLDL and improves atherosclerosis in an animal model. MW: 145.5 kD. Human IgG1
A2387 Anti-Osteopontin Anti-Osteopontin is an antibody used in antigen-specific immunodetection in biological samples. MW: 145.5 kD. Human IgG1
A2388 Mupadolimab (Anti-NT5E / CD73) Mupadolimab (Anti-NT5E / CD73) is a type II humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. MW: 145.5 kD. Human IgG1
A2389 Tarextumab (Anti-NOTCH3) Tarextumab (Anti-NOTCH3) is an anti-Notch2/3 fully human IgG2 monoclonal antibody with anti-tumor activity. MW: 145.5 kD. Human IgG2SA
A2390 Tesnatilimab (Anti-NKG2D / CD314) Tesnatilimab (Anti-NKG2D / CD314) is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody against the immune activating receptor natural-killer group 2, member D receptor protein (NKG2D or KLRK1), with potential immunomodulating and anti-inflammatory activities. MW: 146.5 kD. Human IgG4SP
A2392 Enfortumab (Anti-Nectin-4) Enfortumab (Anti-Nectin-4) is a monoclonal antibody targeting Nectin-4 and has potential for research into urothelial cancer. MW: 145.44 kD. Human IgG1
A2393 Lorvotuzumab (Anti-NCAM1 / CD56) Lorvotuzumab (Anti-NCAM1 / CD56) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine. MW: 145.5 kD. Human IgG1
A2394 Ensituximab (Anti-MUC5AC) Ensituximab (Anti-MUC5AC) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC with specificity for colorectal and pancreatic cancer. MW: 145.5 kD. Human IgG1
A2395 Imaprelimab (Anti-MUC18 / MCAM / CD146) Imaprelimab (Anti-MUC18 / MCAM / CD146) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody with antineoplastic activity. MW: 145.5 kD. Human IgG1
A2396 Abagovomab (Anti-MUC16) Abagovomab (Anti-MUC16) is a murine IgG1 monoclonal anti-idiotype antibody containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125 with potential antineoplastic activity. MW: 145.5 kD. Human IgG1
A2398 Narnatumab (Anti-MSPR / RON / CD136) Narnatumab (Anti-MSPR / RON / CD136) is a fully human monoclonal antibody against RON (recepteur d'origine nantais; macrophage stimulating 1 receptor) with potential antineoplastic activity. MW: 145.5 kD. Human IgG1
A2399 Andecaliximab (Anti-MMP9) Andecaliximab (Anti-MMP9) is a recombinant chimeric IgG4 monoclonal antibody (mAb) that targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. MW: 145.5 kD. Human IgG4SP
A2400 Imalumab (Anti-MIF) Imalumab (Anti-MIF) is a human, recombinant monoclonal antibody (MoAb) against macrophage migration inhibitory factor (MIF), with potential immunomodulating, anti-inflammatory, and antineoplastic activities. MW: 145.5 kD. Human IgG1
A2401 Amatuximab (Anti-Mesothelin) Amatuximab (Anti-Mesothelin) is a chimeric IgG1 monoclonal antibody against human mesothelin with potential anti-tumor activity. Amatuximab specifically targets mesothelin, a cell surface glycoprotein involved in cell adhesion and overexpressed in many epithelial-derived cancer cells. MW: 145.5 kD. Human IgG1
A2402 Anti-Melanotransferrin / CD228 Anti-Melanotransferrin / CD228 is an antibody against the melanotransferrin with potential antineoplastic activity.MW: 145.5 kD. Human IgG1
A2403 Narsoplimab (Anti-MASP2) Narsoplimab (Anti-MASP2) is a monoclonal antibody against mannan-binding lectin (MBL)-associated serine protease-2 (MASP-2), with potential anti-thrombotic and immunomodulating activities. MW: 145.5 kD. Human IgG4SP
A2404 Ontamalimab (Anti-MADCAM1) Ontamalimab (Anti-MADCAM1) is a fully human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1) with potential for the research of Crohn's disease. MW: 145.5 kD. Human IgG2SA
A2405 Lupartumab (Anti-LYPD3 / C4.4A) Lupartumab (Anti-LYPD3 / C4.4A) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of the antibody-drug conjugate Lupartumab Amadotin. MW: 145.5 kD. Human IgG1
A2406 Anti-Ly6E  Anti-Ly6E is an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) with potential antineoplastic activity.MW: 145.5 kD. Human IgG2SA
A2407 Samrotamab (Anti-LRRC15 / LIB) Samrotamab (Anti-LRRC15 / LIB) is a fully human monoclonal antibody against LRRC15. MW: 145.5 kD. Human IgG1
A2408 Simtuzumab (Anti-LOXL2) Simtuzumab (Anti-LOXL2) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2) with potential antineoplastic activity. MW: 145.5 kD. Human IgG4SP
A2409 Ladiratuzumab (Anti-LIV-1 / SLC39A6) Ladiratuzumab (Anti-LIV-1 / SLC39A6) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. MW: 145.5 kD. Human IgG1
A2410 Opicinumab (Anti-LINGO1) Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1 and has potential applications in acute optic neuritis and relapsed multiple sclerosis. MW: 145.5 kD. Human IgG1
A2046 Risankizumab (anti-IL-23) Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's disease. human IGg1, κ
A2411 Polzastobart (Anti-LILRB2 / ILT4 / CD85d) Polzastobart (Anti-LILRB2 / ILT4 / CD85d) is a humanized monoclonal antibody directed against the inhibitory immune checkpoint receptor leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2; immunoglobulin-like transcript 4; ILT4; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Human IgG4SP
A2047 Alirocumab (anti-PCSK9) Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation. human IGg1, κ
A2412 Falbikitug (Anti-LIF) Falbikitug (Anti-LIF) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody against leukemia inhibitory factor (LIF), with potential immunomodulating and antineoplastic activities.  MW: 145.24 kD. Human IgG1
A2048 Necitumumab (anti-EGFR) Necitumumab (anti-EGFR) is an epidermal growth factor receptor (EGFR) antagonist that can be used in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer. human IGg1, κ
A2413 Mibavademab (Anti-LEPR / CD295) Mibavademab (Anti-LEPR / CD295) is a humanized monoclonal antibody against LEPR (Leptin receptor). MW: 145.5 kD. Human IgG4SP
A2414 Anti-LAMP1 / CD107a Anti-LAMP1 / CD107 is a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) with potential antineoplastic activity. MW: 145.5 kD. Human IgG1
A2416 Anti-Klotho Beta Anti-Klotho Beta is an antibody targeting Beta Klotho (KLB). MW: 145.24 kD. Human IgG1
A2417 Anti-KLK2 / Kallikrein 2 Anti-KLK2 / Kallikrein 2 is a radioimmunoconjugate containing h11B6, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets human kallikrein-2 (hK2), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. MW: 145.5 kD. Human IgG1
A2418 Lacutamab (Anti-KIR3DL2 / CD158k) Lacutamab (Anti-KIR3DL2 / CD158k) is a humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. MW: 150 kD. Human IgG1
A2049 Evinacumab(anti-ANGPTL3) Evinacumab is a monoclonal antibody that targets, binds to, and pharmacologically inhibits ANGPTL3, which can act as a complementary agent to other LDL-C lowering regimens for patients aged 12 or older with HoFH. human IGg1, λ
A2419 Lirilumab (Anti-KIR) Lirilumab (Anti-KIR) is a  fully human monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research. MW: 150 kD. Human IgG4SP
A2420 Anti-Integrin b1 / ITGB1 / CD29 Anti-Integrin b1 / ITGB1 / CD29 is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity. MW: 145.5 kD. Human IgG1
A2050 Romosozumab(anti-sclerostin) Romosozumab is a monoclonal antibody that binds to sclerostin (an inhibitor of the Wingless-related integration site (Wnt) signaling pathway). It is a new osteoanabolic drug, that simultaneously increases bone formation and decreases bone resorption. human IGg2, κ
A2421 Efalizumab (Anti-Integrin aL / ITGAL / CD11a) Efalizumab (Anti-Integrin aL / ITGAL / CD11a) is a humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with immunosuppressant activity. MW: 145.5 kD. Human IgG1
A2422 Garetosmab (Anti-INHBA / Activin A) Garetosmab (Anti-INHBA / Activin A) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research. MW: 145.5 kD. Human IgG4SP
A2423 Enokizumab (Anti-IL-9) Enokizumab (Anti-IL-9) is a humanized monoclonal antibody directed against the cytokine interleukin-9 (IL-9), with potential immunomodulating activity. MW: 145.5 kD. Human IgG1
A2424 Anti-IL-7Ra / CD127 Anti-IL-7Ra / CD127 is a monoclonal antibody against human IL-7Rα with therapeutic benefit against T-ALL (T-cell acute lymphoblastic leukemia). MW: 145.5 kD. Human IgG1
A2427 Benralizumab (Anti-IL-5Ra/ CD125) Benralizumab (Anti-IL-5Ra/ CD125) is an afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra) with potential anti-asthmatic activity. MW: 145.5 kD. Human IgG1
A2428 Mepolizumab (Anti-IL-5) Mepolizumab (Anti-IL-5) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. MW: 145.5 kD. Human IgG1
A2431 Talacotuzumab (Anti-IL-3Ra / CD123) Talacotuzumab (Anti-IL-3Ra / CD123) is a humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. MW: 146.06 kD. Human IgG1
A2432 Itepekimab (Anti-IL-33) Itepekimab (Anti-IL-33) is a monoclonal antibody against IL-33. Itepekimab reduces airway inflammation and related tissue damage in previous clinical studies. MW: 145.5 kD. Human IgG4SP
A2433 Nemolizumab (Anti-IL-31Ra) Nemolizumab (Anti-IL-31Ra) is a humanized monoclonal antibody, targeting IL-31Ra. It inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD). MW:145.5 KD. Human IgG2SA
A2434 Daclizumab (Anti-IL-2Ra / CD25) Daclizumab (Anti-IL-2Ra / CD25) is a recombinant monoclonal antibody interleukin-2 receptor antagonist. MW:145.5 KD. Human IgG1
A2435 Basiliximab (Anti-IL-2Ra / CD25) Basiliximab (Anti-IL-2Ra / CD25) is a recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. MW:145.58 KD. Human IgG1
A2437 Tildrakizumab (Anti-IL-23a) Tildrakizumab (Anti-IL-23a) is a humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. MW:145.5 KD. Human IgG1
A2438 Guselkumab (Anti-IL-23) Guselkumab (Anti-IL-23) is a recombinant human IgG1 monoclonal antibody. It targets the key IL-23 and inhibits the production of cytokines lying downstream of the IL-23 signaling pathway and can be used for reatment of psoriatic arthritis, Crohn's disease, and ulcerative colitis. MW : 145.5 KD. Human IgG1
A2439 Anti-IL-22Ra Anti-IL-22Ra is an affinity isolated polyclonal antibody, targeting IL-22R. It is used in the treatment of psoriasis, psoriatic arthritis, atopic dermatitis. MW :145.5 KD. Human IgG1
A2440 Fezakinumab (Anti-IL-22) Fezakinumab (Anti-IL-22) is a monoclonal antibody targeting IL-22. It can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis. MW :145.5 KD. Human IgG1
A2441 Fletikumab (Anti-IL-20) Fletikumab (Anti-IL-20) is a monoclonal antibody, targeting IL-20. It can be used for inflammation research, such as rheumatoid arthritis and psoriasis. MW : 145.5 KD. Human IgG4SP
A2442 Spesolimab (Anti-IL-1RL2 / IL-36R) Spesolimab (Anti-IL-1RL2 / IL-36R) is an humanized antagonistic monoclonal antibody targeting IL-36 receptor. It can be used for treatment of palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP). MW : 145.5 KD. Human IgG1
A2443 Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R) Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. It has the potential for chronic obstructive pulmonary disease (COPD), asthama treatment. MW :145.5 KD Human IgG2SA
A2444 Nidanilimab (Anti-IL-1RAP / IL-1R3) Nidanilimab (Anti-IL-1RAP / IL-1R3) is a fully humanized monoclonal antibody targeting IL1RAP and blocks IL1α and IL1β signaling. It also stimulates the immune system to destroy tumour cells. It can be used in treatment of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). MW :143.56 KD. Human IgG1
A2445 Anti-IL-1R1 / CD121a Anti-IL-1R1 / CD121a is a fully humanized monoclonal antibody that targets interleukin-1 (IL-1), inhibiting the activity of IL-1a and IL-1b. It can be beneficial in treatment of osteoarthritis (OA) and rheumatoid arthritis. MW :145.5 KD. Human IgG2SA
A2446 Canakinumab (Anti-IL-1b) Canakinumab (Anti-IL-1b) is a recombinant human anti-IL-1β monoclonal antibody targeting IL-1β and neutralizing IL-1β signaling. It can be used in treatment of disorders of autoimmune origin like familial mediterranean fever, mevalonate kinase deficiency, tumor necrosis factor receptor-associated periodic syndrome (TRAPS). MW :145.5 KD. Human IgG1
A2447 Bermekimab (Anti-IL-1a) Bermekimab (Anti-IL-1a) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). It prevents tumour-related inflammation. MW :145.5 KD. Human IgG1
A2448 Anti-IL-18 Anti-IL-18 is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD). MW :150 KD. Human IgG1
A2450 Anti-IL-17c Anti-IL-17c is a fully humanized recombinant IgG1 monoclonal antibody targeting IL-17C. It can be used in a clinical treatment of atopic dermatitis. MW :145.5 KD. Human IgG1
A2452 Anti-IL-13Ra1 / CD213a1 Anti-IL-13Ra1 / CD213a1 is a monoclonal antibody targeting IL13RA1. It can be used in research of therapeutic antibody for biological drug discovery. MW :145.5 KD. Human IgG2SA
A2453 Tralokinumab (Anti-IL-13) Tralokinumab (Anti-IL-13) is a fully human IgG4 monoclonal antibody specifically targeting IL-13 with high affinity. It can be used for the research of the atopic dermatitis (AD). MW :145.5 KD. Human IgG4SP
A2454 Abrezekimab (Anti-IL-13) Abrezekimab (anti-IL-13) is a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. It can be used in research of asthma. MW: 145.5 KD. Human IgG1
A2455 Teprotumumab (Anti-IGF-1R / CD221) Teprotumumab (Anti-IGF-1R / CD221) is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab can be used for thyroid-associated ophthalmopathy research.MW: 145.5 KD. Human IgG1
A2456 Ganitumab (Anti-IGF-1R / CD221) Ganitumab (Anti-IGF-1R / CD221) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. MW: 145.5 KD. Human IgG1
A2457 Xentuzumab (Anti-IGF-1) Xentuzumab (Anti-IGF-1) is a recombinant a humanized monoclonal antibody that targets IGF ligands IGF-1 and IGF-2. Xentuzumab inhibits both of IGF-1 and IGF-2 growth-promoting signalling and suppresses AKT activation. MW: 145.5 KD. Human IgG1
A2460 Anifrolumab (Anti-IFNAR1) Anifrolumab (Anti-IFNAR1) is a human monoclonal antibody. It is a type I interferon (IFN) receptor antagonist, that blocks the activity of type I interferon. Anifrolumab can be used in research of systemic lupus erythematosus (SLE). MW: 145.5 KD. Human IgG1
A2461 Sifalimumab (Anti-IFNa1) Sifalimumab (Anti-IFNa1) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. MW: 145.5 KD. Human IgG1
A2462 Feladilimab (Anti-ICOS / CD278) Feladilimab (Anti-ICOS/CD278) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has potential for its use in cancer research. MW: 145.5 KD. Human IgG4PE
A2463 Vopratelimab (Anti-ICOS / CD278) Vopratelimab (Anti-ICOS / CD278) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that binds specifically to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab exhibits antitumor immune response. MW: 145.5 KD. Human IgG1
A2464 Bersanlimab (Anti-ICAM1 / CD54) Bersanlimab (Anti-ICAM1 / CD54) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects. MW: 145.5 KD. Human IgG1
A2465 Anti-HLA-DR Anti-HLA-DR (IMMU-114) is a humanized anti-human leukocyte antigen-DR (HLA-DR) moAb, that depletes APCs and reduces alloreactive T cells. MW: 145.5 KD. Human IgG4SP
A2466 Derlotuximab (Anti-Histone H1) Derlotuximab is a recombinant human monoclonal antibody that targets DNA/histone (H1) complex. It is potentially used in the treatment of Glioblastoma multiforme (GBM), Cancers, brain, malignant glioma, Solid tumors. It is also used in certain immunoassay techniques. MW: 145.5 KD. Human IgG1
A2470 Anti-Hepcidin / HAMP Anti-Hepcidin / HAMP (LY2787106) is a fully humanized monoclonal antibody againsts hepcidin. It is currently in phase I human trials for cancer-related anemia. It binds to hepcidin and prevents its binding to the iron exporting protein ferroportin and prevents hepcidin-induced internalization and degradation of ferroportin and increases ferroportin-mediated iron export. MW: 145.5 KD. Human IgG4SP
A2471 Anti-HBEGF Anti-HBEGF (U3-1565) is a humanized monoclonal antibody against human heparin-binding EGF-like growth factor (HBEGF) and exhibits potential antineoplastic activity. It binds to HBEGF and blocks the binding of HBEGF to the EGF receptors which prevents EGF receptor activation and results in subsequent induction of cell growth signaling. MW: 145.5 KD. Human IgG1
A2472 Indusatumab (Anti-GUCY2C) Indusatumab (Anti-GUCY2C) is an monoclonal antibody that targets GUCY2C (Guanylate cyclase 2C). MW: 145.5 KD. Human IgG1
A2473 Anti-GPRC5D Anti-GPRC5D is a specific antibody against G protein-coupled receptor C5 family member D (GPRC5D). Human IgG1
A2474 Petosemtamab (Anti-GPR49 / LGR5) Petosemtamab (Anti-GPR49 / LGR5) is an monoclonal antibody that targets GPR49/LGR5. It blocks the appearance of metastases and slows the growth of primary tumors in experimental cancer models. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC). MW: 145.5 KD. Human IgG1
A2475 Glembatumumab (Anti-GPNMB) Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. MW: 145.5 KD. Human IgG2SA
A2476 Codrituzumab (Anti-GPC3 / Glypican-3) Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3) which is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth. MW: 150 KD. Human IgG1
A2477 Anti-GPA33 Anti-GPA33 (KRN330) is a monoclonal antibody that targets GPA33, a tumor-associated antigen (TAA) which is overexpressed on the surface of certain tumor cells. It exhibits potential immunostimulatory and antineoplastic activities. MW: 145.5 KD. Human IgG1
A2478 Glenzocimab (Anti-GP6 / Glycoprotein-6) Glenzocimab (Anti-GP6 / Glycoprotein-6) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke. MW: 145.5 KD. Human IgG1
A2480 Anti-GFRAL Anti-GFRAL (NGM120) is a long-acting monoclonal antibody directed against glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), with potential anti-anorexia and anti-cachexia activities. It binds to and blocks GFRAL activity which prevents binding of growth differentiation factor 15 (GDF15; MIC-1) to its receptor GFRAL and prevents GDF15/GFRAL-mediated signaling. MW: 145.5 KD. Human IgG1
A2481 Nadecnemab (Anti-GFRA3) Nadecnemab (Anti-GFRA3) is an IgG4κ antibody targeting GFRA3 (glial cell derived neurotrophic factor family receptor alpha 3). Nadecnemab can be used for research of osteoarthritis of the knee/pain. MW: 145.5 KD. Human IgG4SP
A2482 Apitegromab (Anti-GDF8 / Myostatin) Apitegromab (Anti-GDF8 / Myostatin) is a fully human monoclonal antibody that binds to human promyostatin and latent myostatin with a high degree of specificity, without binding to mature myostatin and other closely related growth factors. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy. MW: 145.5 KD. Human IgG4SP
A2483 Ponsegromab (Anti-GDF15 / MIC-1) Ponsegromab (Anti-GDF15 / MIC-1) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers. MW: 145.5 KD. Human IgG1
A2484 Ecromeximab (Anti-GD3) Ecromeximab (Anti-GD3) is a human-mouse chimeric IgG1 monoclonal antibody with potential antineoplastic activity that targets ganglioside GD3, a surface antigen expressed on many malignant melanoma cells. It binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. MW: 145.5 KD. Human IgG1
A2485 Dinutuximab (Anti-GD2) Dinutuximab (Anti-GD2) is a chimeric mouse/human monoclonal antibody that targets ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. It has potential antineoplastic activity. MW: 145.5 KD. Human IgG1
A2486 Naxitamab (Anti-GD2) Naxitamab (Anti-GD2) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers. MW: 145.5 KD. Human IgG1
A2487 Volagidemab (Anti-GCGR) Volagidemab (Anti-GCGR) is an antagonistic monoclonal antibody (mAb) that targets glucagon receptor (GCGR). Volagidemab can be used in the research of type 1 diabetes (T1D). MW: 145.5 KD. Human IgG2SA
A2488 Tabituximab (Anti-FZD10) Tabituximab (Anti-FZD10) is a humanized monoclonal antibody that targets frizzled class receptor 10 (FZD10). MW: 145.5 KD. Human IgG1
A2489 Vantictumab (Anti-FZD) Vantictumab (Anti-FZD) is a monoclonal antibody targeting the Wnt signaling pathway with potential antineoplastic activity. Vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This results in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. MW: 145.5 KD. Human IgG2SA
A2490 Anti-Fucosyl GM1 Anti-Fucosyl GM1 is a antibody that recognizes and targets the fucosyl form of ganglioside GM1. MW: 145.5 KD. Human IgG1
A2491 Mirvetuximab (Anti-FOLR1) Mirvetuximab (Anti-FOLR1) is a monoclonal antibody targeting FOLR1 (folate receptor 1). Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). MW: 145.2 KD Human IgG1
A2492 Farletuzumab (Anti-FOLR1) Farletuzumab (Anti-FOLR1) is a humanized monoclonal antibody with high affinity for FRα. It is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer. MW: 144.12 KD Human IgG1
A2494 Anti-FGFR4 / CD334 Anti-FGFR4 / CD334 (U3-1784) is a human monoclonal antibody targeting FGFR4 (human fibroblast growth factor receptor 4), with potential antineoplastic activity. It blocks activation of FGFR4, which inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. MW: 145.5 KD. Human IgG1
A2495 Vofatamab (Anti-FGFR3 / CD333) Vofatamab (Anti-FGFR3 / CD333) is a monoclonal antibody targeting FGFR3. Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). MW: 145.5 KD. Human IgG1
A2496 Anti-FGFR3 / CD333 Anti-FGFR3 / CD333 (LY3076226) is a human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor type 3). MW: 145.5 KD. Human IgG1
A2499 Burosumab (Anti-FGF23) Burosumab (Anti-FGF23) is a neutralizing antibody, targeting human fibroblast growth factor 23 (FGF23). It can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. MW: 145.5 KD. Human IgG1
A2500 Rozanolixizumab (Anti-FcRn (FCGRT & B2M)) Rozanolixizumab (Anti-FcRn (FCGRT & B2M)) is a high-affinity humanized monoclonal antibody, targeting human neonatal Fc receptor (FcRn) and is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases. MW: 150 KD. Human IgG4SP
A2501 Lumiliximab (Anti-FceR2 / CD23) Lumiliximab (Anti-FceR2 / CD23) is a monoclonal antibody targeting CD23, that inhibits allergen-induced responses. MW: 145.5 KD. Human IgG1
A2502 Emicizumab (Anti-F9 / Factor IX) Emicizumab (Anti-F9 / Factor IX) is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research. MW: 145.5 KD. Human IgG4SP
A2503 Garadacimab (Anti-F12 / Factor XII) Garadacimab (Anti-F12 / Factor XII) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research. MW: 145.5 KD. Human IgG4SP
A2504 Osocimab (Anti-F11 / Factor XI) Osocimab (Anti-F11 / Factor XI) is an antibody targeting Factor FXI. FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects. MW: 145.5 KD. Human IgG1
A2505 Anti-ETBR Anti-ETBR (DEDN6526A) is a humanized immunoglobulin (Ig) G1 monoclonal antibody targeting endothelin B receptor (ETBR). MW: 145.5 KD. Human IgG1
A2511 Anti-EphA2 (MEDI-547) Anti-EphA2 (MEDI-547) is a fully human IgG1 monoclonal antibody that is used for targeting EphA2. It selectively binds to cells expressing the EphA2 receptor. MW: 145.12 KD. Human IgG1
A2512 Adecatumumab (Anti-EpCAM / TROP1 / CD326) Adecatumumab (Anti-EpCAM / TROP1 / CD326) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status. MW: 145.5 KD. Human IgG1
A2514 Carotuximab (Anti-Endoglin / CD105) Carotuximab (Anti-Endoglin / CD105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions. MW: 145.5 KD. Human IgG1
A2515 Parsatuzumab (Anti-EGFL7) Parsatuzumab (Anti-EGFL7) is a humanized monoclonal antibody targeting EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition. MW: 145.5 KD. Human IgG1
A2516 Anti-EFNA4 Anti-EFNA4 (PF-06647263) is a antibody targeting EFNA4. MW: 145.5 KD. Human IgG1
A2518 Tamrintamab (Anti-DPEP3) Tamrintamab (Anti-DPEP3) is an ADC Antibody targeting dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research. MW: 145.5 KD. Human IgG1
A2519 Navicixizumab (Anti-DLL4) Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4/VEGF. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD. Human IgG2SA
A2520 Demcizumab (Anti-DLL4) Demcizumab (Anti-DLL4) is a monoclonal antibody taregting DLL4. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models. MW: 145.5 KD. Human IgG2SA
A2521 Rovalpituzumab (Anti-DLL3) Rovalpituzumab (Anti-DLL3) is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC). MW: 145.5 KD. Human IgG1
A2522 Anti-DKK1 Anti-DKK1 (BHQ880) is a humanized monoclonal antibody targeting Wnt antagonist Dickkopf-1 (DKK1). It binds to and inhibits DKK1, enhancing signaling through the Wnt pathway, which result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease. Human IgG1
A2523 Ulocuplumab (Anti-CXCR4 / CD184) Ulocuplumab (Anti-CXCR4 / CD184) is a fully human IgG4 antibody, targeting CXCR4. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. MW: 144.84 KD. Human IgG4SP
A2525 Eldelumab (Anti-CXCL10 / IP-10) Eldelumab (Anti-CXCL10 / IP-10) is a humanised monoclonal antibody (IgG1 type) targeting CXCL10. Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease. MW: 145.5 KD. Human IgG1
A2526 Quetmolimab (Anti-CX3CL1 / Fractalkine) Quetmolimab (Anti-CX3CL1 / Fractalkine) is a humanized monoclonal antibody targeting CX3CL1. MW: 150 KD. Human IgG2SA
A2530 Anti-CSF3 / G-CSF Anti-CSF3 / G-CSF (CSL324) is an antibody targeting CSF3. It is useful for studying growth factor signaling. MW: 145.5 KD. Human IgG4SP
A2531 Anti-CSF2Rb / CD131 Anti-CSF2Rb / CD131 (CSL311) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis. MW: 145.5 KD. Human IgG4SP
A2532 Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. MW: 145.5 KD. Human IgG4SP
A2533 Otilimab (Anti-CSF2 / GM-CSF) Otilimab (GSK 3196165) is an humanized monoclonal antibody targeting GM-CSF (granulocyte-macrophage colony-stimulating factor). Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor. MW: 145.5 KD. Human IgG1
A2535 Lampalizumab (Anti-Complement Factor D) Lampalizumab (Anti-Complement Factor D) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research. MW: 145.5 KD. Human IgG1
A2536 Avdoralimab (Anti-Complement C5aR1) Avdoralimab (Anti-Complement C5aR1) is a fully human IgGκ monoclonal antibody targeting the complement C5a receptor 1 (C5aR1), that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research. MW: 145.5 KD. Human IgG1
A2537 Ravulizumab (Anti-Complement C5) Ravulizumab (Anti-Complement C5) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. MW: 145.5 KD. Human IgG2SA
A2538 Eculizumab (Anti-Complement C5) Eculizumab (Anti-Complement C5) is a long-acting humanized monoclonal antibody targeting against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research. MW: 145.5 KD. Human IgG1
A2539 Tesidolumab (Anti-Complement C5) Tesidolumab (Anti-Complement C5) is a fully-human IgG1/λ monoclonal antibody targeting against Complement C5. Tesidolumab blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex. MW: 145.5 KD. Human IgG1
A2540 Anti-Complement C3 Anti-Complement C3 (NGM621) is an antibody targeting Complement C3. It binds with high affinity to intact human C3. It is used in the research for treatment of Geographic Atrophy. MW: 145.5 KD. Human IgG1
A2541 Anti-Clusterin Anti-Clusterin (AB-16B5) is a humanized IgG2 antibody targeted against clusterin. It is an inhibitor of the epithelial to mesenchymal transition. Anti-Clusterin (AB-16B5) can be used for cancer research. MW: 145.5 KD. Human IgG2SA
A2542 Tepoditamab (Anti-CLEC12A / CD371) Tepoditamab (Anti-CLEC12A / CD371) is a bispecific monoclonal antibody that targets and binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research. MW: 145.5 KD. Human IgG1
A2543 Tinurilimab (Anti-CEACAM6 / CD66c) Tinurilimab (Anti-CEACAM6 / CD66c) is an monoclonal antibody targeting against CEACAM6 and CD66c. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. MW: 145.5 KD. Human IgG2SA
A2544 Tusamitamab (Anti-CEACAM5 / CEA / CD66e) Tusamitamab (Anti-CEACAM5 / CEA / CD66e) is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine, which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative). MW: 145.5 KD. Human IgG1
A2545 Anti-CEACAM1 / CD66a Anti-CEACAM1 / CD66a (CM-24) is a humanized monoclonal immunoglobulin G4 (IgG4) antibody targeting CEACAM1 and CD66a, with potential immunomodulating and antineoplastic activities. It blocks the binding of CEACAM1-expressing cancer cells to CEACAM1-expressing immune cells and abrogates CEACAM1-mediated immunosuppression. MW: 145.5 KD. Human IgG1
A2051 Human IgG1 isotype control Human IgG1 isotype control is suitable for use as a non-targeting isotype control in various in vitro and in vivo studies, is the isotype control of human IgG1κ antibody. human IGg1, κ
A2546 Actoxumab (Anti-Cdiff Toxin A) Actoxumab ( (Anti-Cdiff Toxin A) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab targeting TcdB. MW: 145.5 KD. Human IgG1
A2052 Human IgG4 isotype control Human IgG4 isotype control is suitable for use as a non-targeting isotype control in various in vitro and in vivo studies, is the isotype control of human IgG4κ antibody. human IGg4, κ
A2547 Anti-CDH6 / K-Cadherin Anti-CDH6 / K-Cadherin (DS-6000a) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting against the tumor-associated antigen cadherin-6. MW: 145.5 KD. Human IgG1
A2548 Anti-CDH3 / P-cadherin Anti-CDH3 / P-cadherin (PF-03732010) is a antibody targeting p-cadherin. It binds to and inhibits the activity of p-cadherin which may inhibit tumor cell invasion and proliferation in p-cadherin expressing tumor cells. MW: 145.5 KD. Human IgG1
A2549 Anti-CD98 Anti-CD98 (KHK2898) is an antibody targeting CD98. MW: 145.5 KD. Human IgG1
A2550 Polatuzumab (Anti-CD79b) Polatuzumab (Anti-CD79b) is a monoclonal antibody which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. MW: 145.5 KD. Human IgG1
A2551 Milatuzumab (Anti-CD74) Milatuzumab (Anti-CD74) is a humanized monoclonal antibody targeting CD74, a integral membrane protein. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death. MW:145.5 KD. Human IgG1
A2552 Itolizumab (Anti-CD6) Itolizumab (Anti-CD6) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis, COVID-19. MW:145.5 KD. Human IgG1
A2553 Alemtuzumab (Anti-CD52) Alemtuzumab (Anti-CD52) is a humanized monoclonal antibody targeting against CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. MW:145.5 KD. Human IgG1
A2554 Anti-CD46 Anti-CD46 (FOR46) is a human monoclonal antibody targeting against CD46. It specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. MW:145.5 KD. Human IgG1
A2555 Bivatuzumab (Anti-CD44v6) Bivatuzumab (Anti-CD44v6) is a humanized monoclonal antibody targeting against CD44v6 that could acts as a sarcoma target for CAR-redirected CIK cells. MW:145.5 KD. Human IgG1
A2300 Anti-VEGFR3 / FLT4 Anti-VEGFR3 / FLT4 is a fully-human monoclonal antibody directed against (VEGFR-3; Flt-4) with antiangiogenic activity.Anti-VEGFR3 / FLT4 also plays a critical role in the embryonic vascular system development. Human IgG1
A2556 Ibalizumab (Anti-CD4) Ibalizumab (Anti-CD4) is a humanised IgG4 monoclonal antibody, targeting C4. It prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research. MW:145.5 KD. Human IgG4SP
A2301 Icrucumab (Anti-VEGFR1 / FLT1) Icrucumab (Anti-VEGFR1 / FLT1) is a humanized Anti-VEGFR-1 IgG1 monoclonal antibody, with potential anti-tumor and anti-metastatic agent. It also act as a therapeutic anti-angiogenic agent in different pathological contexts. Human IgG1
A2557 Teplizumab (Anti-CD3e) Teplizumab (Anti-CD3e) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes. MW:145.5 KD. Human IgG1
A2302 Anti-VEGFC Anti-VEGFC is a fully human monoclonal antibody targeting the human vascular endothelial growth factor C (VEGFC or Flt4 ligand) with potential antiangiogenic activity and lymphangiogenesis. It also prevent metastasis. MW :145.5 KD. Human IgG1
A2303 Anti-VEGFB Anti-VEGFB (CSL346) is an antibody targeting VEGFA. MW:150 KD. Human IgG4SP
A2559 Galiximab (Anti-CD28L / CD80) Galiximab (Anti-CD28L/CD80) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody targeting against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma. MW:145.5 KD. Human IgG1
A2560 Anti-CD28 Anti-CD28 (FR104) is an antibody targeting CD28. MW:145.5 KD. Human IgG2SA
A2305 Ranibizumab (Anti-VEGFA) Ranibizumab (Anti-VEGFA) is a recombinant humanized IgG1 monoclonal antibody fragment that inhibits (VEGF-A) and degrades angiogenesis throughout the body and in the eye also interrupts the interaction of VEGF with its receptors, and thus prevents the subsequent growth of new blood vessels. Human IgG1
A2561 Ocrelizumab (Anti-CD20) Ocrelizumab (Anti-CD20) is a recombinant humanized monoclonal IgG1 antibody that selectively targets CD20 antigen present on B-cells. It is used to treat relapsing remitting multiple sclerosis. MW:145.5 KD. Human IgG1
A2306 otlertuzumab (Anti-TSPAN26 / CD37) Otlertuzumab (Anti-TSPAN26 / CD37) is a humanized monoclonal antibody and anti-CD37 protein therapeutic. It is a potent monospecific protein used in treatments of refractory follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), or Waldenström's macroglobulinaemia (WM) Human IgG1
A2562 Siplizumab (Anti-CD2) Siplizumab (Anti-CD2) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells. MW:145.5 KD. Human IgG1
A2307 Tezepelumab (Anti-TSLP) Tezepelumab (Anti-TSLP) is a potent human IgG2 monoclonal antibody that inhibits the binding of TSLP to the TSLP receptor, and also has potent efficacy and mechanism in asthma. Human IgG2
A2563 Tafasitamab (Anti-CD19) Tafasitamab (Anti-CD19) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigen CD19. It is used in combination with allogeneic NK cell therapy in treatment of B-cell non-Hodgkin's lymphoma. MW:145.5 KD. Human IgG1
A2308 Anti-TSHR Anti-TSHR are unconjugated polyclonal antibodies derived from rabbi. Anti-TSHR are pathophysiologic, and also increases their significance in the diagnosis of autoimmune thyroid diseases and Graves' disease. Human IgG1
A2564 Inebilizumab (Anti-CD19) Inebilizumab (Anti-CD19) is an monoclonal antibody targeting CD19 antigen present on B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research. MW:145.5 KD. Human IgG1
A2309 Flanvotumab (Anti-TRP1 / TYRP1) Flanvotumab (Anti-TRP1 / TYRP1) is a monoclonal antibody directed against the melanosomal membrane protein gp75 (or Tyrosinase-Related Protein 1 (TRP1)) with potential immunostimulatory and antineoplastic activities. MW: 145.5 kD. Human IgG1
A2565 Anti-CD163 Anti-CD163 (OR2805) is a human immunoglobulin G1 (IgG1) monoclonal antibody targeting CD163 (scavenger receptor cysteine-rich type 1 protein M130), with potential immunomodulating and antineoplastic activities. It targets and binds to CD163 expressed on immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME), and prevents the binding of CD163 to its ligands. MW:145.5 KD. Human IgG1
A2566 Atibuclimab (Anti-CD14) Atibuclimab (Anti-CD14) is a chimeric monoclonal antibody targeting CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. MW:145.5 KD. Human IgG4SP
A2311 Anti-TrkA / NTRK1 Anti-TrkA / NTRK1 is a non-conjugated, rabbit-derived monoclonal antibody targeting TrkA. MW : 145.5 KD. Human IgG1
A2312 Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) is a humanized monoclonal antibody that specifically recognizes and binds to CD70 molecular. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells and shows inhibitory efficacy against Burkitt’s lymphoma. MW : 150 kDa. Human IgG1
A2568 Mogamulizumab (Anti-CCR4 / CD194) Mogamulizumab (Anti-CCR4 / CD194) is a defucosylated humanized recombinant monoclonal antibody targeting CCR4. Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL). MW:145.5 KD. Human IgG1
A2313 Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) is a humanized immunoglobulin monoclonal antibody that targets TNFSF5. MW : 150 kDa. Human IgG1
A2314 Oxelumab (Anti-TNFSF4 / OX40L / CD252) Oxelumab (Anti-TNFSF4 / OX40L / CD252) is a human monoclonal antibody against the OX40 ligand (OX40L) with the potential to be used for asthma research. MW : 145.5 kDa. Human IgG1
A3173New Minretumomab (CC-49) Minretumomab (CC-49) is a monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab can be used in cancer and immunity research. Human IgG1-Kappa
A2571 Anti-CCL5 / RANTES Anti-CCL5 / RANTES (NI-0701) is a antibody tageting CCL5. MW:145.5 KD. Human IgG2SA
A2572 Anti-CCL20 Anti-CCL20 (GSK3050002) is a humanized IgG1κ antibody with high binding affinity to the human chemokine, CCL20. MW:145.5 KD. Human IgG4SP
A2317 Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) is a fully humanized IgG2κ monoclonal antibody that targets the B-cell growth factor APRIL (TNFSF13), with the potential to treat IgA nephropathy (IgAN). MW : 145.5 KD. Human IgG2SA
A2318 Anti-TNFSF12 / TWEAK Anti-TNFSF12 / TWEAK is a humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. It is used to treat renal interstitial fibrosis. MW : 145.5 KD. Human IgG1
A2574 Nimacimab (Anti-CB1 / CNR1) Nimacimab (Anti-CB1/CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases. MW:145.5 KD. Human IgG4SP
A2575 Anti-CB1 / CNR1 Anti-CB1 / CNR1 (GFB-024) is a recombinant humanised monoclonal antinody that is used for targeting of CB1 receptor. MW:145.5 KD. Human IgG1
A2320 Pateclizumab (Anti-TNFSF1 / TNFb) Pateclizumab (Anti-TNFSF1 / TNFb) is a humanized monoclonal antibody that blocks and depletes anti-lymphotoxin α (LTα). It has a great potential for the treatment of rheumatoid arthritis (RA). MW : 145.5 KD. Human IgG1
A2576 Erenumab (Anti-CALCRL / CGRPR) Erenumab (Anti-CALCRL/CGRPR) is a fully human monoclonal antibody targeting CGRP receptor (calcitonin gene–related peptide receptor). Erenumab can be used for the prevention of episodic migraine. MW:145.5 KD. Human IgG2SA
A2321 Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. MW : 146.5 KD. Human IgG4SP
A2577 Galcanezumab (Anti-CALCA / CGRP) Galcanezumab (Anti-CALCA/CGRP) is a humanized IgG4 monoclonal antibody targeting the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research. MW:145.5 KD. Human IgG4SP
A2322 Brentuximab (Anti-TNFRSF8 / CD30) Brentuximab (Anti-TNFRSF8 / CD30) is a chimeric monoclonal antibody targeting anti-CD30 with antineoplastic activity. It has the potential to alter the disease course of non-MF/SS CTCLs. MW : 145.38 KD. Human IgG1
A2578 Girentuximab (Anti-CA9 / Carbonic anhydrase 9) Girentuximab (Anti-CA9 / Carbonic anhydrase 9) is a chimeric monoclonal antibody that targets and binds to carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). MW:145.5 KD. Human IgG1
A2323 Varlilumab (Anti-TNFRSF7 / CD27) Varlilumab (Anti-TNFRSF7 / CD27) is a human monoclonal antibody with activity against the CD27 receptor. It exhibits potential immunostimulating and antineoplastic activity. MW : 150 KD. Human IgG1
A2579 Sutimlimab (Anti-C1s) Sutimlimab (Anti-C1s) is a humanized monoclonal antibody that targets the C1s protein in the classical complement pathway. It can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase. MW:145.5 KD. Human IgG4SP
A2324 Iscalimab (Anti-TNFRSF5 / CD40) Iscalimab (Anti-TNFRSF5 / CD40) is a non-depleting IGg1 monoclonal antibody targeting CD40. Iscalimab can be used for research on Graves' hyperthyroidism and autoimmune diseases. MW : 145.5 KD. Human IgG1
A2580 Anti-C1q Anti-C1q (ANX005) is a recombinant antibody against C1q. It inhibits its function as the initiating molecule of the classical complement cascade. It is used in research of autoimmune and neurodegenerative diseases. MW:145.5 KD. Human IgG1
A2325 Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) is a monoclonal antibody targeting TNFRSF4. MW : 145.5 KD. Human IgG1
A2581 Icatolimab (Anti-BTLA / CD272) Icatolimab (Anti-BTLA / CD272) is a recombinant human monoclonal antibody which targets human BTLA protein. It neutralizes the interaction between BTLA and HVEM(Herpesvirus entry mediator). MW :145.5 KD. Human IgG4SP
A2326 Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) is a humanized monoclonal antibody against the OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for research on autoimmune diseases. MW : 145.5 KD. Human IgG1
A2582 Onvatilimab (Anti-B7-H5 / VISTA) Onvatilimab (Anti-B7-H5 / VISTA) is a human IgG1κ monoclonal antibody that targets and bind to VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). It has an anti-tumor activity. MW : 150 KD. Human IgG1
A2327 Ragifilimab (Anti-TNFRSF18 / GITR / CD357) Ragifilimab (Anti-TNFRSF18 / GITR / CD357) is an anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody with potential immune checkpoint modulating activity. MW : 145.5 KD. Human IgG1
A2583 Prezalumab (Anti-B7-H2 / ICOSL / CD275) Prezalumab (Anti-B7-H2 / ICOSL / CD275) is a human IgG2 monoclonal antibody targeting ICOSL and BAFF. It demonstrates studies for systemic lupus erythematosus arthritis. It is used in the research of Sjogren's syndrome cutaneous lupus erythematosus, psoriasis and systemic lupus erythematosus (SLE).MW :145.5 KD. Human IgG2SA
A2329 Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) is a fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. MW : 145.5 KD. Human IgG1
A2330 lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) Lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. MW : 145.5 KD. Human IgG1
A2331 Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) with a Kd of 1 nM and 0.8 nM for the long form and the short form of DR5, respectively. Conatumumab induces apoptosis via caspase activation. MW : 144.96 KD. Human IgG1
A3174New Mosunetuzumab (Anti-CD20 & CD3e) Mosunetuzumab (Anti-CD20 & CD3e) is expressed from CHO. The heavy chain type is IgG1, and the light chain type is hukappa. MW: 146.72 kDa. human IGg1
A2332 Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. MW : 145.5 KD. Human IgG2SA
A2588 Aducanumab (Anti-Amyloid Beta) Aducanumab (Anti-Amyloid Beta) is a selective human monoclonal antibody targeting aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.MW :145.5 KD. Human IgG1
A2333 Tomaralimab (Anti-TLR2 / CD282) Tomaralimab (Anti-TLR2 / CD282) is a humanized immunoglobulin (Ig) G4 monoclonal antibody directed against toll-like receptor type 2 (TLR2) with potential anti-inflammatory and antineoplastic activities. It has the potential for research on Myelodysplastic Syndromes (MDS). MW : 145.5 KD. Human IgG4SP
A2589 Birtamimab (Anti-Amyloid Alpha) Birtamimab(Anti-Amyloid Alpha) is an investigational monoclonal antibody that specifically and selectively targets and clear the amyloid. It can be used for treatment to remove amyloid from the vital organs, and research of light chain amyloidosis.MW :145.5 KD. Human IgG1
A2334 Tisotumab (Anti-Tissue factor / CD142) Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody that targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. MW : 145.5 KD. Human IgG1
A2590 Murlentamab (Anti-AMHR2) Murlentamab (Anti-AMHR2) is a humanized anti-AMHRII antibody targeting AMHRII. It suppresses tumor growth, stimulates the anti-tumor adaptive immune response through naive macrophage orientation and TAM reprogrammation, in ovarian tumor cells. MW :145.5 KD. Human IgG1
A2591 Cinpanemab (Anti-Alpha-synuclein) Cinpanemab(Anti-Alpha-synuclein) is a human-derived monoclonal antibody that targets and binds to α-synuclein. It can be used for the research of Parkinson's disease. MW : 146.98 KD. Human IgG1
A2336 Fresolimumab (Anti-TGFb1) Fresolimumab (Anti-TGFb1) is a pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) beta 1, 2, and 3 with potential antineoplastic activity. MW : 145.5 KD. Human IgG4SP
A2592 Praluzatamab (Anti-ALCAM / CD166) Praluzatamab (Anti-ALCAM / CD166) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). It can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates)which is used for research of cancers. MW : 150 KD. Human IgG1
A2044 Omalizumab (anti-IgE) Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research. Human IgG1
A2337 Concizumab (Anti-TFPI) Concizumab (Anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. MW : 145.5 KD. Human IgG4SP
A2593 Enibarcimab (Anti-Adrenomedullin) Enibarcimab (Anti-Adrenomedullin) is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody targeting the vasoprotective peptide adrenomedullin. It can be used for acute heart failure, COVID-19 infections and septic shock research. MW : 145.5 KD. Human IgG1
A2338 Ontuxizumab (Anti-TEM1 / Endosialin / CD248) Ontuxizumab (Anti-TEM1/endosialin/ CD248) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with potential anti-angiogenic and antineoplastic activities. MW : 145.5 KD Human IgG1
A2594 Ascrinvacumab (Anti-ACVRL1 / ALK-1) Ascrinvacumab (Anti-ACVRL1 / ALK-1) is a human IgG2 monoclonal antibody targeting ALK-1. It can be used for the treatment of hepatocellular carcinoma (HCC), in patients with advanced solid tumors. It also demonstrates its use in antiangiogenic therapy. MW : 150 KD. Human IgG2SA
A2339 Anti-TCR Anti-TCR is a monoclonal antibody targeting TCR. MW : 145.5 KD. Human IgG2SA
A2595 Bimagrumab (Anti-ACVR2B) Bimagrumab (Anti-ACVR2B) is a human monoclonal antibody targeting activin type II receptor (ActRII). It can be used for the treatment of pathological muscle loss and weakness. MW : 150 KD. Human IgG1
A2340 Anti-TBFbR2 Anti-TBFbR2 is a monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity. MW : 145.5 KD  Human IgG1
A2341 Zagotenemab (Anti-Tau) Zagotenemab (Anti-Tau) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. It has the potential to be used in Alzheimer's disease research. MW : 145.5 KD Human IgG4SP
A2053 Monalizumab (Anti-Human CD159a) Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors. Human IgG4-Kappa
A2342 Indatuximab (Anti-Syndecan-1 / CD138) Indatuximab (Anti-Syndecan-1/CD138) is an antibody against Syndecan-1. MW : 145.5 KD Human IgG4SP
A2343 Vandortuzumab (Anti-STEAP1) Vandortuzumab (Anti-STEAP1) is a recombinant monoclonal antibody that specifically targets STEAP1. It has potential for the treatment of prostate cancer. MW : 145.5 KD. Human IgG1
A2344 Bexmarilimab (Anti-STAB1) Bexmarilimab (Anti-STAB1) is a monoclonal antibody directed against common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1; stabilin-1; FEEL-1) with an IC50 value of 4.51 nM and potential immunomodulatory and antineoplastic activities. MW : 145.5 KD. Human IgG4SP
A2345 Sonepcizumab (Anti-Sphingosine-1-phosphate) Sonepcizumab (Anti-Sphingosine-1-phosphate) is a humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. MW : 145.5 KD. Human IgG1
A2347 Sirtratumab (Anti-SLITRK6) Sirtratumab (Anti-SLITRK6) is a humanized Igγ2 monoclonal antibody against SLIT and NTRK-like family 6 (Slitrk6). MW : 145.5 KD. Human IgG2SA
A2348 Anti-SLC44A4  Anti-SLC44A4 is a fully human IgG2k monoclonal antibody targeting SLC44A4 (AGS-5) with potential antineoplastic activity. MW : 145.5 KD. Human IgG2SA
A2349 Anti-SLC40A1 Anti-SLC40A1 is a monoclonal antibody targeting SLC40A1. It has the potential to do research on mineral absorption, insulin receptor recycling, and transmembrane transporter activity. MW : 145.5 KD. Human IgG4SP
A2350 Lifastuzumab (Anti-SLC34A2) Lifastuzumab (Anti-SLC34A2) is a humanized monoclonal antibody targeting NaPi2b. MW : 145.5 KD. Human IgG1
A2040 Leronlimab (anti-CCR5) Leronlimab (anti-CCR5) （PRO 140; Vyrologix）is a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. It is being investigated as a potential therapy in the treatment of HIV infection. Human IgG4
A2351 Upifitamab (Anti-SLC34A2) Upifitamab (Anti-SLC34A2) is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize an ADC compound, Upifitamab rilsodotin, used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer. MW : 145.5 KD. Human IgG1
A2352 Idactamab (Anti-SLC1A5 / ASCT2) Idactamab (Anti-SLC1A5 / ASCT2) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used to prepare MEDI7247, a potent and specific ADC targeting ASCT2 (SLC1A5). MW : 145.5 KD. Human IgG1
A2354 Anti-SLAMF6 / CD352  Anti-SLAMF6 / CD352 is a humanized monoclonal antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) with potential antineoplastic activity. MW : 145.5 KD Human IgG1
A2355 Anti-SIRPg Anti-SIRPg is a recombinant human antibody that act againts anti-SIRPG (anti-Signal-Regulatory Protein Gamma). MW : 145.5 KD Human IgG4SP
A2356 Refanezumab (Anti-Siglec-4a / MAG) Refanezumab (Anti-Siglec-4a / MAG) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. MW : 145.5 KD Human IgG1
A2357 Vadastuximab (Anti-Siglec-3 / CD33) Vadastuximab (Anti-Siglec-3 / CD33) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine. MW : 150 KD. Human IgG1
A2358 Inotuzumab (Anti-Siglec-2 / CD22) Inotuzumab (Anti-Siglec-2 / CD22) is a humanized IgG4, κ monoclonal antibody that targets CD22. Inotuzumab can be used for the research of acute lymphoblastic leukaemia and non-Hodgkin lymphoma. MW : 144.78 kD. Human IgG1
A2359 Anti-Sialyl-Lewis A Anti-Sialyl-Lewis A is a human monoclonal antibody against the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19-9) with potential antineoplastic activity.MW : 145.5 kD. Human IgG1
A2360 Dezamizumab (Anti-Serum Amyloid P / SAP) Dezamizumab (Anti-Serum Amyloid P / SAP) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody with potential anti-amyloid activity. MW : 144.18 kD. Human IgG1
A2361 Pepinemab (Anti-SEMA4D / CD100) Pepinemab (Anti-SEMA4D / CD100) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), which is a regulator of neuronal development and plays a role in a variety of cellular processes. MW : 145.5 kD. Human IgG4SP
A3176New Human IgG2sa isotype control Human IgG2sa isotype control is suitable for use as a non-targeting isotype control in various in vitro and in vivo studies, is the isotype control of human IgG2sa antibody. Human IgG2SA-Kappa
A2363 Anti-RTN4 / NOGO Anti-RTN4 / NOGO is an antibody acting against anti-RTN4. MW : 145.4 kD. Human IgG1
A2364 Palivizumab (Anti-RSV-F) Palivizumab (Anti-RSV-F) is a humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. MW : 145.5 kD. Human IgG1
A2365 Rosmantuzumab (anti-RSPO3) Rosmantuzumab (OMP-131R10) is an immunoglobulin (Ig) G1 humanized monoclonal antibody targeting human R-spondin 3 (RSPO3) with potential immunostimulating and antineoplastic activities. MW: 145.5 kD. Human IgG1
A2367 Anti-ROBO1(Asclepius Technology patent anti-Robo1 CAR) Anti-ROBO1 (Asclepius Technology patent anti-Robo1 CAR) is a bispecific antigen-binding construct targeting ROBO1, with a single-chain variable region antibody fragment ScFV binding to the surface antigen of immune cells and a Slit2D2 protein fragment binding to the surface antigen Robo1 of tumour cells.MW: 145.5 kD. Human IgG1
A2368 Roledumab (Anti-RHD / CD240d) Roledumab (Anti-RHD / CD240d) is a human recombinant monoclonal anti-RhD antibody with the potential to prevent RhD allo-immunization. MW: 145.5 kD. Human IgG1
A2369 Anti-RGMC / HFE2 Anti-RGMC / HFE2 is a humanized monoclonal antibody directed against the bone morphogenetic proteins (BMPs) co-receptor hemojuvelin (HJV) with potential to treat anemia of inflammation and other forms of anemia. MW: 145.5 kD. Human IgG1